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Abstract
The self-association of proteins to form dimers or higher-order oligomers is a very common
phenomenon in biology. Protein dimerization or oligomerization acts as a control tool
for the execution of functions in many biological systems. Three systems were studied
by computational methods in this thesis. Cyclic diguanylic acid (CDG) is a ubiquitous
messenger involved in bacterial signaling networks. CDG can form an intercalated dimer
and bind at the inhibition site of PleD. MD simulations were carried out for the CDG
dimer as well as the analogue of CDG (endo-S-CDG) in solution and binding to the
PleD protein. It was demonstrated, that dimeric CDG is only marginally stabilized even
in high concentration. The results help the fundamental understanding of c-di-GMP
and preventing biofilm formation. Insulin is a small protein that plays an eminent role
in controlling glucose uptake in cells. Insulin can associate as a dimer which leads to
diabetes. The key role of the B24 residue for insulin dimerization was identified. Our
work provided an insight for designing analogues of human insulin and thus a therapy for
diabetes.
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1 Overview
Proteins are organic macromolecules which constitute one of the four major building
blocks of molecular biology and are essential to all organisms. The majority of protein
tasks in living cells are mediated by protein-protein interactions. Protein-protein in-
teractions occur when two or more proteins bind together, often in order to carry out
their biological function. Self-association of proteins to form dimers and higher-order
oligomers is a very common phenomenon. It is evident that protein dimerization acts as
a control tool for the execution of functions in many biological systems. The formation of
a dimer can be responsible for enzyme activation. For example, the dimerization of the
diguanylate cyclase PleD of C. crescentus will lead to synthesizing the bacterial second
messenger c-di-GMP, which is involved in the transition of Caulobacter cells from the
motile to the sessile form. On the other hand, two c-di-GMP monomers form an interca-
lated dimer which binds at the inhibition site of PleD and induces product inhibition
(see Chapter 4). Conversely, dimerization can inhibit an active monomeric protein, e.g,
insulin and lead to disease. Thus, identification of protein-protein interactions is at the
heart of functional genomics and prediction of protein-protein interactions is also crucial
for drug discovery (see Chapter 5).
The aim of this thesis is to characterize the dimerization and ligand-binding in
important biological systems using computational methods. The free energies of the
systems which can describe their tendencies to associate and react were investigated
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using computer simulations. Parameters which were missing were parametrized before
Molecular Dynamics Simulations were employed . Then numerous theoretical tools were
used to illustrate the structural changes upon dimerization.
2
2 Introduction
“Nature has simplicity and therefore a great beauty.”
Richard P. Feynman
2.1 Proteins
Proteins are large polymeric organic compounds made of amino acids, which together
with nucleic acids, lipids and saccharides constitute the four major types of biological
molecules. Proteins play an essential role in biology. They are involved in nearly every
aspect of physiology and biochemistry, carrying out the most important tasks in living
organisms. Ultimately it is the three-dimensional structure of proteins that determines
their function. Therefore, it is crucial to study the details of the three-dimensional
structure of the protein. The basic cornerstone for the three dimensional structure
is the amino acid, which consists of an α-carbon, an amine (−NH2), a carboxyl acid
(−COOH), a side chain and one more hydrogen. There are left-handed (l-amino acids)
and right-handed (d-amino acids) isomers due to asymmetry of the “α-carbon”. Only the
side chain varies between different amino acids. Two amino acids are connected through
a peptide bond, which is an amide bond formed by the reaction of an α-amino group
(−NH2) of one amino acid with the carboxyl group (−COOH) of another. In general,
the basic twenty standard amino acids can be classified by the properties of their side
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chain into four groups: hydrophobic, hydrophilic, acidic, and basic. The first two refer
to nonpolar and polar side chains, respectively, while the last two may be negatively or
positively charged respectively according to the surrounding pH and their pKa.
The main interactions, i.e., hydrogen bonding and the hydrophobic effect, that drive them
to fold into intricate secondary, tertiary and quaternary functional structures (Figure 2.1)
are weak compared to their own conformational entropy, which is one of the reasons
that proteins often exist in large scale so they have to cooperate with each other to
keep themselves in their native structure. Besides, many proteins are believed to be
“disordered”, i.e., unstable in solution. The structures of disordered proteins are not
“random”, but have a significant residual structure and differ from one another primarily
due to the different sequence of amino acids, which results in folding of the protein into
a characteristic three-dimensional shape that determines its activity. In the “disordered”
state, a protein exists in an ensemble of conformers. It has been found that the main
driving forces in folding globular proteins is to pack the hydrophobic side-chains in the
interior of the molecule, the so called hydrophobic core; the hydrophilic backbones are
hydrogen-bonded, forming secondary structure elements; the hydrophobic side-chains of
the α-helices and of the β-sheets often interact to form higher-order secondary structure
motifs.1,2 The ability to fold provides the basis for the many diverse functions that
proteins are responsible for within living organisms, e.g., molecular motors, cell signal-
ing, catalyzing reactions, transporting, transmitting information from DNA to RNA,
traversing membranes to yield regulated channels, and forming the building blocks of
viral capsids.3
2.1.1 Structure and Function
Most of the three-dimensional macromolecular structure data in the Protein Data Bank5
were obtained mainly by: X-ray crystallography (> 80%), solution nuclear magnetic
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resonance (NMR technique) (∼ 16%) and theoretical modeling (2%). The first two
techniques are experimental methods and provide a resolution at the level of distinguishing
individual atoms. In X-ray crystallography, the first step is protein molecule crystallization
which is as much an art as science. The X-ray beam is directed on a crystalline sample,
the crystalline atoms cause it to diffract into many specific directions. This can produce
a three-dimensional picture of the density of electrons within the crystal and provide
the 3D model of the protein. However, this technique is limited to molecules that form
regular crystals. Membrane proteins and flexible fibril-like proteins are very difficult to
crystallize.
Nuclear magnetic resonance (NMR) spectroscopy, relies on the principle that the
nuclear magnetic moment is aligned with the electromagnetic field, and elucidates the
solution structure of small proteins using chemical shifts (describing the local structure)
and nuclear Overhauser effect (NOE) data (measuring short atomic distances). While
these two methods share certain similarities, they are two complementary techniques
for probing a wide range of structural and dynamical properties of macromolecules.
Combination of NMR and X-ray diffraction data is able to obtain more precise models.6–8
Table 2.1: X-ray crystallography and NMR are complementary techniques
X-ray crystallography NMR
long time scale (s ∼ hours), static
structure
short time scale (ns ∼ s), protein folding
single crystal, purity solution, purity
<100 kDa, domain, complex < 30 kDa, domain
all atomic properties by a Fourier
transformation
chemically specific, local structural
information by NOE, J-coupling/chemical
shift
active or inactive functional active site
electron density atomic nuclei, chemical bonds
resolution limit 2-3.5 A˚ resolution limit 2-3.5 A˚
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Figure 2.1: Biomolecular structure of the protein PleD. (PDB code:2V0N4) Proteins have
complex shapes based on four levels of structure: primary structure; secondary
structure; tertiary structure and quaternary structure. Primary structure–a
protein’s unique linear sequence of amino acids; secondary structure–alpha-
helix or beta-pleated sheets; tertiary structure–determined by the interaction
of the amino acid’s side groups with their environment, generating the 3-
dimensional shape of the protein molecule. The folded areas may be held
together by disulfide linkages in some proteins.
6
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A major goal of structural biology is to predict the three dimensional structures of
proteins from the sequence,9 many proteins are simply too large for NMR analysis and
can not be crystallized for X-ray diffraction. Therefore, there is a huge gap between
available experimentally determined structures and residue sequences that have been
determined. Protein modeling, such as homology modeling is an alternative strategy
that is being applied to obtain structural information if experimental techniques fail.
Homology modeling is a knowledge-based prediction of protein 3D structures. In homology
modeling, a protein sequence with unknown structure (the target) is aligned with one or
more protein sequences with known structures (the templates). The method is based on
the principle that homologous proteins have similar structure and is a fast tool in drug
discovery. Homology modeling obtains more reliable results than pure theory such as
ab initio modeling. Figure 2.2 shows the common four processes for building homology
models: template selection, target-template alignment, model construction, and model
quality evaluation.
In the first step, the program/server compare the sequence of the target protein
to the template protein in the protein data bank (PDB)10. The most popular servers
such as BLAST11, and FASTA12 perform the searching and give a list of known protein
structures that matches the sequence when the sequence identity between target and
template sequences is above 30%. If it is below 30%, alternative strategies based on
multiple sequence alignment13,14 have to be used. Once a suitable template has been
selected, it should be aligned to the target using programs such as t-coffee15, Expresso15,
PSI-BLAST12 and PROBCONS16. The sequence alignment step is crucial for the ac-
curacy of the homology model, as no modeling procedure can recover from incorrect
alignment. Based on the template structure and the alignment, in the third step the
model for the target protein is constructed (including backbone generation, loop modeling,
sidechain modeling, and model optimization). Several methods can be employed such as
those based on rigid-body assembly (SWISS-MODEL17,18, Composer19, 3D-JIGSAW,
7
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Figure 2.2: The key processes for homology modeling.
PrlSM20, CONGEN21,22), or based on spatial restraint, (Modeller23) whereas side-chains
and loops an be modeled with other processes. If no suitable template structure is
available for comparative modeling, de novo modeling methods also called ab initio
modeling may be used. There are many factors will lead homology models to fail, i.e.,
errors in side-chain prediction, alignment errors, errors in the regions without templates,
misalignment, incorrect templates. Therefore, it is necessary to evaluate the homology
model. Currently, there are many programs and web servers such as PROCHECK24,
WHATIF25, VERIFY3D26 and ANOLEA27 available for assisting the evaluation. Typical
applications of a homology model in drug discovery require a very high accuracy of the
local side chain positions in the binding site. A large number of homology models have
been built over the years, including antibodies28 and proteins in human biology and
8
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medicine29,30.
There are some other techniques to study different aspects of structures of cellular
components, such as Hydrogen-deuterium (H/D) exchange, a chemical reaction where a
covalently bonded hydrogen atom is replaced by a deuterium atom upon changing the
solvent from H2O to D2O, or vice versa. FRET detects distance changes in real-time. All
of these techniques provide essential tools to determine protein structure and moreover
the protein-protein interactions which are at the core of the entire interaction system of
any living cell.
2.1.2 Allostery
Allostery is the phenomenon that a change such as binding an effector molecule at one
site (allosteric site), affects the activity at another site which will controls processes
such as signal transmission, catalysis, receptor trafficking, turning genes on or off and
apoptosis. Effectors which enhance the protein activity are referred as allosteric activa-
tors, while those that decrease the protein activity are called allosteric inhibitors. The
distance between an allosteric site and the functional part of the protein could be several
tens of A˚ngstro¨ms. The classical allosteric views such as Monod-Wyman-Changeux
(MWC)31, and Koshland-Ne´methy-Filmer (KNF)32 described allostery regulation via a
conformational change. The MWC model described the transition as a concerted action
between two co-existing, discrete states (R and T); and the KNF model formulates it
as a sequential, induced conformational change by the binding event at the first site
which is responsible for the allosteric effect. The old views indicate that: first, there
are only two states R and T which exist in a ratio governed by an equilibrium constant
when the ligand is absent; second, allostery involved a shape change in the substrate
binding site; third, the allosteric signal is transmitted via a single pathway.33,34 The new
9
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views indicate that: first, proteins exist in ensembles instead of just two conformational
states; second, allostery is a thermodynamic phenomenon and can be driven by enthalpy,
enthalpy and entropy, or entropy. Allostery can work without a change in shape. Third,
the existence of multiple conformational and dynamic states implies multiple pathways
through which the strain energy is released from the allosteric site. If the enthalpy change
does not reverse the free-energy change due to the change in entropy, entropy may be
the factor responsible for the ligand binding.33–39
2.2 Protein-Protein Interactions
The majority of protein tasks in living cells are mediated by protein-protein interactions.
Protein-protein interactions occur when two or more proteins bind together, in order to
carry out the biological function. Protein interactions have been studied from the perspec-
tives of biochemistry, quantum chemistry, molecular dynamics, chemical biology, signal
transduction and other metabolic or genetic networks. If one can identify the function of
at least one of the components with which the protein interacts, its function pathway can
be assigned3. Through the network of protein-protein interactions, it is possible to map
cellular pathways and their intricate cross-connectivity. Identification of protein-protein
interactions is at the heart of functional genomics. The types of protein-protein com-
plexes can be classified as homodimeric proteins, heterodimeric proteins, enzyme-inhibitor
complexes and antibody-protein complexes.40 Prediction of protein-protein interactions
is also crucial for drug discovery.3,41 In order to predict protein-protein interactions, it is
necessary to figure out the chemical and physical features of the associations, including
the shape complementary to the organization and physical/chemical contributions to
their stability. In the next section, we will introduce protein dimerization, which is a
subset of protein-protein interactions.
10
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2.2.1 Protein Dimerization
In biochemistry, a dimer is a macromolecular complex formed by two, usually non-
covalently bonded, macromolecules like proteins or nucleic acids, and can be classified
as homodimer or heterodimer.42 Homodimers, which are present in abundance in the
Protein Data Bank (PDB5), are the simplest case of non-covalent self-assembly in proteins.
Dimerization is a subset of protein-protein interactions. The self-assembly of proteins
to form dimers and higher oligomers is a common theme. Self-assembly can help to
minimize genome size while maintaining the advantages of modular complex formation.43
It was proposed that there are three pathways for the evolution of dimers: 1) formation
of a functional dimer directly without going through an ancestor monomer. This kind of
homodimeric proteins are permanent assemblies and their polypeptide chains assemble at
the time they fold. 2) formation of an energetically stable monomer and then mutating its
surface residues. This kind of complex involves proteins that fold separately and remain
in monomeric forms until they meet and associate. 3) a domain swapping mechanism,
replacing one segment of the monomer by an equivalent one from an identical chain in
the dimer.44,45 Homomultimeric proteins are responsible for the diversity and specificity
of many pathways, ion channels, activities of enzymes, mediation and regulation of gene
expression, receptors, cell adhesion processes and so on.
It is evident that protein dimerization acts as a control tool for the execution of
functions in many biological systems. The formation of a dimer can be responsible for
enzyme activation. For example, PleD is a protein that is involved in the transition of
Caulobacter cells from the motile to the sessile form. It has been suggested that the
activation can be triggered via the dimerization of the D1/D2 domains in PleD monomers
and bring two DGC domains close as a condition for the condensation reaction to occur.4
Conversely, dimerization can inhibit an active monomeric enzyme, e.g. insulin. Insulin,
a protein that controls glucose uptake in cells, performs the biological function in its
11
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monomeric form. However, under physiological conditions, the monomers are ready to
aggregate to dimers and lose their critical biological function.46
Protein-Protein Interface Proteins interact through interfaces, which consist of residues
or fragments that belong to two different subunits. Figure 2.3 is one of the examples
of protein-protein interfaces. The subunits of a multimeric protein are identical in a
homomultimeric protein, whereas in a heteromultimeric protein they are different. There
are several fundamental properties people use to characterize protein-protein interfaces.40
1) Compared to a transient interaction which is continuously forming and dissociating,
the interface of obligated interaction is larger, more conserved and tends to have more
hydrophobic residues, whereas transient interfaces consist of more polar residues.47 2) The
interfaces of homodimers on average are more hydrophobic and bury twice as much protein
surfaces as in complexes. 3) For “weak” transient homodimers, monomers and dimers can
exist at physiological concentration with dissociation constants in the micro-molar scale.
The weak homodimers have smaller contact areas between protomers and the interfaces
are usually more planar and polar. In contrast, the “strong” transient dimers often
experience large conformational changes upon association/dissociation and have larger,
less planar and sometimes more hydrophobic interfaces.48 4) If the interface is larger
than 1000 A˚2, the complex will undergo conformational changes upon complexation.49,50
Besides, there are several criteria that are used to define interface residues:1 a) the
distance between two CA atoms belonging to each chain respectively is less than 9.0
A˚, b) the distance between any two atoms of two residues from the different chains is
less than 5.0 A˚, c) the van der Waals energy between the residues is less than −0.5
kcal/mol, d) all atoms or amino acid residues in the monomer that lost more than 0.1 A˚2
solvent accessible surface area in the dimer are regarded as interface atoms or residues.51
Criteria have been defined for these residues to be considered as belonging to the interface.
12
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Figure 2.3: Illustration of protein − protein interface. The figure represents two interact-
ing proteins (insulin monomer, PDB code: 4INS). In monomer A: chain A is
colored in light blue and chain B is in dark blue. In monomer B: chain A is
colored in light green and chain B is in dark green. Interacting residues from
the two monomers are shown with surface representation while the rest of
the proteins are illustrated with ribbon representations.
The chemical properties involved in these residues are key factors to understand and
determine the architecture of the interfaces.52–55
Protein-Protein Interaction Forces Protein-protein interactions are mainly driven by :
Covalent Bonds (∼ 60 kcal/mol) Chemical bonds due to the sharing of electrons
pairs between atoms; short-ranged, directional and strong. For single, double and triple
carbon-carbon bonds, one finds approximate energy values of 83, 142 and 196 kcal/mol
respectively.
Electrostatic Interactions (∼ 6 kcal/mol) Such as ion pairs and salt bridges.
Attractive electrostatic interactions between oppositely charged residues, i.e. nitrogen
13
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atoms in the side-chains of His, Arg and Lys as positively charged groups and oxygens in
the side-chains of aspartic and glutamic acids as negatively charged groups. A distance
of less than or equal to 4 A˚ between the involved atoms is typical for these interactions.1
“The energy penalty paid due to the desolvation of the charged residues may not be
recovered by favorable interaction among the charged residues [...]. Calculating the
electrostatic field in a protein molecule correctly is thus akin to hitting a moving target
using a shotgun with a bent barrel while being in the middle of an earthquake.”53
Hydrogen Bonds (∼ 1.8−6 kcal/mol) H-bonds are attractive, relatively weak,
non-bonded interactions between a hydrogen atom (“donor”) and an highly electronega-
tive atom (“acceptor”), e.g. nitrogen or oxygen. The electron belonging to the hydrogen
is strongly pulled towards the oxygen; the hydrogen atom must be covalently bonded
with an electronegative atom and can bond with another electronegative atom of another
molecule.56
van der Waals (vdW) Interactions (' 0.6 kcal/mol) The van der Waals inter-
actions are formed by fluctuations in the electric dipoles of two atoms. The charge in
one atom will induce a dipole in the other atoms, which makes the two atoms attract
each other. It is a weak interaction, the interaction energy is comparable to and often
lower than the thermal vibrational energy (∼ 0.6 kcal/mol). When two molecules are
near each other in a liquid, the distance of closest approach (vdW radii) is generally
greater than the sum of their covalent radii.57
Hydrophobic Effects (' 0.6 kcal/mol) A primarily entropic effect arising from
the rearrangement of hydrogen bonds (loss of water entropy) between solvent molecules
(i.e. water) around non-polar solute (demonstrated in Figure 2.4). This is the entropic
driving force for self-association of non-polar groups in water.58
14
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Figure 2.4: Hydrophobic effect. (a) Bulk water molecules without any constraint which
are highly mobile and have a high state of entropy which is favorable. (b)
Hydrophobic protein surface - surface waters are “frozen”. They reorient and
place the hydrogen bonding sites facing the solvent. They are less mobile and
the entropy is decreased, which costs energy. Adapted from58.
S-S Bridge (∼ 60 kcal/mol) Covalent bond between pairs of cysteins in many
native structures of proteins. Prerequisite for proper folding and biological function; ther-
modynamic stabilization of the native structure by forming conformational constraints
within the protein.58,59
Compared to covalent bonds, all of the noncovalent interactions are known to be
relatively weak interactions. However, small stabilizing interactions can add up and lead
to significant contributions to the overall stability of a conformer. Reversible protein
aggregation usually results from non-covalent protein interactions while covalent aggrega-
tion benefits from formation of a chemical bond, such as a disulfide bridge.60
15
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Binding Hot Spots Protein-protein interactions are critically reliant on just a few
‘hot spot’ residues at the interface. Hot spots make a dominant contribution to the
binding free energy and can disrupt the interaction if they are mutated to alanine.61
Chothia and Janin62, found that the binding hot spot may be any H-bond or ion pairs
in the interface. Mutation of one of the residues forming the ion pair on one side to
alanine will cause its partner on the other side to remain unpaired and decrease the
binding energy.63 However, a study by Wells found some exceptions. The mutation of
amino acids that make important hydrogen or ionic bonds across the interface to alanine
caused only minimal effect on the binding energy. One possible explanation was that
after removal of the hydrogen acceptor, the donor can shift and find another acceptor
to form a new hydrogen bond. At present, two algorithms are considered to be fairly
accurate in predicting the amino acids which will be a hot spot.64,65 Both are based on
the computational calculation results of binding free energy between the interface by
decomposing in terms of H-bonds, ionic interactions, vdW interactions and desolvation
of part of the amino acids. In general, a hot spot amino acid is defined as the one which
decreases ∆G by 2 kcal/mol when mutated to alanine.61
Point Mutations A point mutation, or substitution, is a type of mutation. It can
be induced by chemicals or malfunction of DNA replication, by exchanging a single
nucleotide for another.66 As the difference between the original and the new amino acid
is the side chain, for computational modeling techniques, it can essentially be yielded
by removing or replacing the side chain but conserving the backbone atoms, (i.e. for a
mutation to alanine, the side chains need to be removed and only the beta carbon kept).
Proteins are marginal, mutation of some residues, especially on the hot spot, may change
the thermodynamic equilibrium. This may make the protein either less stable, which
16
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lowers the effective concentration of protein and affects its biochemical function67,68,
or more stable, which causes a loss of flexibility and increases the rigidity. The lower
flexibility of a protein will affect ligand binding, allosteric effects and degradation.69
Computational modeling can be used as a tool to understand and predict the effects of
mutations. It is obvious that rearrangements of the protein structure are necessary to
accommodate the changes of amino acid size owing to mutation. It has been repeatedly
observed that proteins are surprisingly robust to site mutations, and can endure multiple
substitutions with little change in structure, stability, or function.70 Mutations of key
amino acids or hot spot residues will induce rearrangement of the protein and affect the
stability or the enzyme’s specificity. The mutations will affect the protein structure by a)
disruption of the hydrophobic core through over-packing using a large side chain instead
of the original small chain, or through cavity formation by replacing a larger side chain
with a smaller one, or putting a charged/polar residue in the core; b) removal of residues
forming disulphide bridges, or salt bridges, or polar interactions, or hydrogen bonding
partners; c) replacement of charged/polar residues on the surfaces with hydrophobic ones;
d) mutations at ligand binding sites, catalytic sites, or allosteric sites, or other sites of
specific function in proteins.
2.2.2 Thermodynamics and Protein Dimerization
The native protein conformation must be energetically stable. From a thermodynamic
point of view, for protein folding, the major stabilizing contributions are the hydrophobic
effect and hydrogen bonds, while the major destabilizing contributions to the stability
of the folded state is the conformational entropy of the polypeptide chain. Therefore,
the Gibbs free energy barrier for folding is determined by the unfavorable loss in con-
figurational entropy upon folding and the gain in stabilizing native interactions. For
example, the transformation of a long chain to a specific compact structure results in
17
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significant entropical loss due to the restricted motion of the backbone and the side
chains. Under physiological conditions, proteins exists in their native structure because
the favorable enthalpic term arising from the solvent and protein interactions exceeds
in magnitude the unfavorable entropic term. The free-energy difference between the
folded and the unfolded state, is marginal and on the order of 5−10 kcal/mol.58 Since
the pioneering work of Anfinsen,71 protein folding has become a popular subject in
statistical physics. The energy landscape theory72–74 has opened a new research direction
for protein folding. It suggests that the most realistic model of a protein is a minimally
frustrated heteropolymer with a funnel-like landscape biased towards the native structure.
Other recent reviews have been published.75,76
Protein aggregation is affected by environmental conditions, e.g. temperature, pH
and the concentration of components.77 A dimer can be formed spontaneously in a
thermodynamically stable state when the two proteins are confined in a small enough
region, i.e. being surrounded by other macromolecules.78 Compared to protein folding,
electrostatics can enhance association rates while destabilizing the final complex.79–82
Hydrogen bonds and ion pairs contribute more to the stability of protein binding than
to protein folding, while the contribution of the hydrophobic effect to protein-protein
associations is not as strong as in protein folding.1,81,83–85
It is worth mentioning that in protein dimerization, when two subunits come together
and form the interface, the layer of “frozen” water (see Figure2.4) will release from each
surface and become mobile to form H-bonds in all directions, thus, increasing the entropy
and having a lower (more favorable) free energy. The hydrophobic interaction here is
not a positive attraction of the two hydrophobic surfaces, but the water that drives the
subunits together. The interaction (van der Waals) between the hydrophobic surface and
the water was approximately as favorable as that with the other hydrophobic surface,
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and water molecules have a much stronger interaction with each other than with the
subunit interface.
2.2.3 Diseases Caused by Protein Dimerization
Protein misfolding and aggregation is the reason for many protein conformational diseases,
including neurodegenerative (e.g. Alzheimer’s, Huntington’s, and Parkinson’s diseases,
familial British and Danish dementias), systemic (e.g. type II diabetes, light chain
amyloidosis) and other (e.g. cystic fibrosis) diseases.76,86,87
Figure 2.5: A proteostasis network comprising pathways represented by the arrows. Im-
balances in proteostasis often lead to disease. Potential therapies of diseases of
proteostasis can be yielded by shifting the equilibria toward active forms with
small ligands, or replacing aberrant proteins, or modulating the pathways with
agents that influence pathways such as transcription, translation, degradation
and translocation using molecules like siRNAs to modulate concentrations of
chaperones, disaggregates and signal pathways. Adapted from88.
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Diabetes is a very common disease which can be very dangerous if not treated. There
are two types of diabetes. Type I is an autoimmune disease in which the immune system
attacks its own insulin-producing cells by mistake, so that insufficient amounts of insulin
are produced. Type II is insulin resistance, which means that the cells do not react
to insulin the way they are supposed to. Insulin is a hormone, which is produced in
the pancreas as a hexamer and is a main regulator of the glucose levels in the blood.
When we eat, glucose levels rise, and insulin is released into the bloodstream as a
monomer. The insulin acts like a key, opening up cells so they can take in the sugar
and use it as an energy source. Usually insulin dissociates from its hexameric storage
form through an intermediate dimer state to the bioactive monomer before binding
to its transmembrane insulin receptor. The interface which the insulin monomer uses
to bind to the receptor, is the same one that forms dimer and hexamer. Thus, once
the monomers form the dimers or hexamers, they can not bind to the receptors and
subsequently, lose their biological function which leads to diabetes. Therefore, under-
standing the dynamics of insulin dissociation is critical for devising formulations for the
treatment of insulin-dependent diabetes which will be reported in detail in a later chapter.
Bacterial biofilm formation is involved in life-threatening infectious diseases, such as
cystic fibrosis, or the colonization of medical devices. Cyclic diguanosine-monophosphate
(c-di-GMP) is a ubiquitous second messenger that regulates cell surface-associated traits
in bacteria and thus is important for biofilm formation. It is produced from 2 molecules
of GTP by the activity of digunaylate cyclases (DGCs) and is degraded by specific
phosphodiesterases(PDE) into 5’-phosphoguanylyl-(3’-5’)-guanosine (pGpG); pGpG is
subsequently split into two GMP molecules. Through the interaction with different
receptors, such as PilZ- containing proteins, c-di-GMP negatively modulates cell motility
and traits associated with bacterial virulence and stimulates several biofilm-associated
functions. c-di-GMP signaling has been important for the development of anti-biofilm or
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anti-virulence drugs. The concentration of c-di-GMP influences the biofilm formation or
dissolution and thus cause diseases or not. c-di-GMP is ready to form dimers, or higher
aggregates in solution. Analogues of c-di-GMP have been designed, and it was found that
they selectively target binding proteins.89 This is helping to study c-di-GMP signaling in
bacteria and may become lead compounds for the design of anti-biofilm agents. Chapter
4 will present the investigations in detail.
Development of new therapeutic solutions is an expensive and time-consuming process.
Progress in computer power makes it possible to simulate systems involving protein-ligand
and protein-protein interactions with millions of atoms. This opens the possibility to
tackle more physiologically relevant biological problems, and computational simulations
become an essential tool in modern drug design and development. In the next section,
some of these simulation techniques available for protein-protein interaction are reviewed.
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2.3 Computational Simulations Methods
“...all things are made of atoms, and that everything that living things do can be
understood in terms of the jigglings and wigglings of atoms”
Richard P. Feynman
2.3.1 Atomistic MD Simulations
Molecular dynamics (MD), first developed in the late 1970s, is a computer simulation of
physical movements of atoms and molecules over time, according to Newton’s second law
of motion
Fi(t) = miai(t) (2.1)
where Fi is the force exerted on particle i, mi is the mass of particle i and ai is the
acceleration of particle i. The force can also be expressed as the gradient of the potential
energy
Fi = −∇iV (2.2)
Combining the above two equations yields
−dV
dri
= mi
d2ri
dt2
(2.3)
where V is the potential energy of the system and describes how the particles in the
simulation interact with each other and with the environment. Newton’s equation of
motion can then relate the derivative of the potential energy to the changes in position
as a function of time.
The forces between the particles and potential energy are defined by molecular
mechanics force fields. Classical force fields consider the contributions of various atomic
forces that govern molecular dynamics as the interactions between atoms, including
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bonds, angles, dihedral angles, electrostatic and van der Waals terms
Vff =
∑
Vbonds +
∑
Vangles +
∑
Vdihe +
∑
Velec +
∑
VvdW (2.4)
where each term can be expressed as a function of the atomic coordinates
Vbond =
∑
kr(r − re)2
r
(2.5)
Vangle =
∑
kθ(θ − θe)2
θ
(2.6)
Vdihe =
∑
kφ(1 + cos(nφ− δ))
Φ
(2.7)
Velec =
1
4pi0
∑ qiqj
rij
rij
+ - (2.8)
VvdW =
∑
εij
[(
Rmin,ij
rij
)12
− 2
(
Rmin,ij
rij
)6] rij
(2.9)
The first three terms represent the “bonded” interactions while the latter two describe
the “non-bonded” interactions. Chemical bonds and bond angles are modeled using
simple springs (Eq. 2.5 -2.6) and dihedral angles (Eq. 2.7) are modeled using a sinusoidal
function. Non-bonded forces arise due to van der Waals interactions, modeled by the
Lennard-Jones potential (Eq. 2.9), and electrostatic interactions, modeled by Coulomb’s
law (Eq. 2.8). kr, kθ, kφ is the bond, angle, and dihedral angle force constant, respectively.
re and θe are equilibrium values, n is the periodicity of the dihedral and δ is the phase
which governs the position of the maximum. qi, qj are the partial charges on atoms i and
j and 0 is the vacuum dielectric constant. ij is the Lennard-Jones well depth, Rmin,ij
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is the finite distance at the Lennard-Jones minimum. r−12ij is an empirical repulsive
term, describing Pauli repulsion at short ranges due to overlapping electron orbitals.
The r−6ij term describes the attraction at long ranges and can be obtained from theory.
The functional form of the attractive term has a clear physical meaning, which the
repulsive term lacks. The exponent value of the former is chosen for computational
convenience. In principle, the nonbonded energy terms between every pair of atoms which
are more than two bonds apart or belonging to different molecules, should be evaluated.
However, the details of nonbonded treatment depend on the system and the method
used for the system. In general, there are two main ways to handle the nonbonded
interaction. One method is to truncate the interactions at a pre-defined distance, which is
faster but less accurate. Another one is using Ewald summation,90 which is more accurate.
Eq. 2.4 shows a minimal model for force fields. There are several classical force fields
commonly used in molecular dynamics simulations, including AMBER91, CHARMM92,93,
OPLS94,95, and GROMOS96, which are often used with a software that bears the same
name. All of them are parameterized in a different way but generally give similar re-
sults. Force field parameters can be obtained from ab initio calculations or by fitting
of calculated system properties to experimental data. Compared to Eq. 2.4, some force
fields add more terms, such as improper dihedral terms and the Urey-Bradley (1 - 3 bond
length) terms in CHARMM, to improve the description of vibrational spectra and out
of plane motions. Some more terms were introduced, such as CMAP.97,98 A number of
studies have demonstrated good agreement between computational and experimental
measurements of macromolecular dynamics.
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2.3.2 Accuracy Improvement and Other Methods
Although molecular dynamics simulations have achieved significant successes in studying
biological systems, the utility is still limited mainly by two aspects: a) the force fields
require further refinement to be more accurate99,100; b) the high computational demands
prohibit simulations longer than microsecond timescale,101 which may cause inadequate
sampling of conformational states in many cases, e.g. binding pocket configuration in
drug design.
Bond 
Stretching
Hydrogen
Bond
Side-chain
filps α-helix β-hairpin Protein folding Subunit
association
MD Simulation
X-ray, NMR, Fluorescence, UV-VIS, IR, Raman
H/D exchange
10-15 10-12 10-9 10-6 10-3 100 Time [s]
Figure 2.6: Several timescales involved in protein association. The color changes in
the axis represent the different timescale and amplitude [A˚] of the protein
motions. Yellow and light green: Local motion with the amplitude 0.001−0.1
A˚. Light green: Medium-scale motion with the amplitude 0.1−10 A˚. Dark
green: Large-scale motion with the amplitude 1−100 A˚. Light blue: Large-
scale motion with the amplitude 10−100 A˚. Dark Blue: Global motion with
amplitude max 10 A˚.
To overcome the challenges in force field refinement (besides more accurate parame-
ters, i.e. force constants and partial charges), better functional forms for describing the
potential are essential. Using Eq. 2.8 - Eq. 2.9, the long-range intermolecular interactions
are simply expressed by a coulomb potential (Eq. 2.8) instead of electrostatics, induction
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and dispersion. Although dispersion can be approximately covered by the Lennard-Jones
potential attractive term Eq. 2.9, induction is completely neglected. To address these
problems, for bonded terms, anharmonic functional potentias instead of the simple
harmonic potentias were introduced. For the nonbonded terms, e.g., multipole moments
can be used to replace the point charges in the electrostatic interaction and a Morse-
potential can be used for describing covalent bonds. Additionally, new terms for missing
types of interatomic interactions can be added, i.e. inter- and intramolecular electronic
polarization. So far, a generally accepted polarizable force field has not been available
but is under development,102,103 and future implementations will lead to improvement of
accuracy.
For classical MD simulation, the most CPU intensive task is to evaluate the potential
(force field) as a function of the particles’ internal coordinates. The most expensive part
in energy evaluation is the nonbonded term which is scaled by O(n2). Another factor for
the cost of CPU time is the size of the integration timestep, the time internal between
evaluations of the potential energy which needs to be chosen roughly 10 times smaller
than the fastest vibrational frequency in the system (in the range 1 - 2 fs for atomistic
resolution). The timestep value can be extended by using algorithms, i.e. SHAKE,104
which fixes the vibration of the fastest atoms (hydrogens). Aside from algorithms, novel
hardware has been used and made great progress towards overcoming the time-scale
limitations of classical MD simulation, i.e. graphics-processing-units (GPUs) which can
be developed to speed up the MD simulation by an order of magnitude105–107, or special
purpose MD hardware like Anton101 and MDGRAPE108.
ab initio MD simulation In ab initio molecular dynamics, quantum mechanical methods
are used to calculate the potential energy of a system “on the fly” for conformations
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in a trajectory. The Born-Oppenheimer approximation, as the basis of ab initio MD
simulation, is used to solve Schro¨dinger equation by separating nuclear and electronic
wavefunctions. In Born-Oppenheimer MD simulations, the motion of electrons (by solving
Schro¨dinger equations) and motion of nuclei (by solving Newtonian equations)is solved
at the same time
Hˆe|Ψ0〉 = E0|Ψ0 (2.10)
mi
d2ri
dt2
= −dE0
d~ri
(2.11)
where He is the electronic Hamiltonian, Ψ0 is the wavefunction, and E0 is the eigen-
energy. In these simulations, the electronic Schro¨dinger equation is solved at each step
and the nuclei are propagated classically on the potential energy surface. The most
computationally time consuming part at each timestep is the calculation of the electronic
structure which can be handled by different levels of methods, such as density functional
theory (DFT),109,110 Møller-Plesset second order (MP2),111 and semi-empirical methods
with different levels of basis set leading to different accuracy of the results. It is obvious
that ab initio simulation can yield more accurate results, however their use is severely
limited to very small systems (i.e. ∼ 100 atoms) due to the intensive computational cost.
QM/MM In quantum mechanics/molecular mechanics (QM/MM) methods, the “active
site” is treated by QM methods and the rest of the system is handled by MM force fields.
Therefore, within the QM region, the motions of atoms are described by ab initio methods
as described above, while for the MM region, the motions of atoms are propagated by an
empirical potential. All the methods are compromised between accuracy and speed.112–114
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Coarse-graining As mentioned above, molecular modeling can provide insight in bio-
logical systems in all-atom detail within the limitations of simulation time and system
sizes of less than 100 ns and 10 nm respectively. To address problems arising from larger
time-scale and length-scale, or the time-scale and length-scale gap between computational
and experimental methods of studying biological systems, alternative techniques are
needed. A possible way to extend molecular modeling and bridge it with experimental
techniques is using coarse-grained methods. Compared to an all-atom description, coarse-
graining methods represent a system by a reduced number of degrees of freedom, such
as using “pseudo-atoms” to represent groups of atoms instead of every atom explicitly.
Computationally, coarse-graining has great advantages: a) with a smaller number of
“pseudo-atoms” or beads, it decreases the computational requirements and accelerates
the speed of molecular dynamics simulations. b) the coarse-graining potentials tend
to be softer than the atomistic one, so that larger integration time steps can be used.
c) coarse-graining reduces molecular friction and therefore smoothes the free energy
landscape which makes the dynamics faster. The reduced representations, so called
coarse-graining models, such as discontinuous molecular dynamics (CG-DMD)115 and
Go-models116,117 can be used to tackle the problem. In coarse-graining methods, param-
eterization (potential of interaction, i.e. van der Waals interactions with other groups
have the proper distance-dependence, and the same for the bonds, angles, dihedrals etc),
mapping (between atoms and beads, i.e in the MARTINI118–120 force field, the beads can
be used in normal size 4:1 mapping or small size 3:1 mapping) is not easy to yield. The
results need to agree with experimental data or all-atom simulations. Compared to other
molecular modeling methods, coarse-graining provides substantial savings in computer
time, but at the cost of accuracy and lose the microscopic information. The higher the
level of coarse-graining that is used, the lower the accuracy of the result can be. Overall,
coarse-graining, as a complementary tool to experiments and atomic simulation, can
identify the important degrees of freedom and provide a big picture of the main structural
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mechanisms in biological systems. The applications of coarse-graining methods include in
protein folding, liquid crystals, packaging of DNA, RNA structure in the ribosome, etc.
29

3 Determination of Protein-Protein Binding
Affinities
For the understanding of protein aggregation it is important to be able to predict protein-
protein binding reliably, but it is a challenging task. Protein-protein binding can be
obligate, meaning that the subunits are not observed on their own in vivo, or transient,
meaning continuously forming and dissociating in vivo.3,49,121 From a physical chemical
standpoint, any two proteins can interact. The question is under what conditions and at
which strength. The Gibbs free energy upon complex formation — also called binding
free energy — can be used to assess how stable the interactions are. Experimentally, the
Gibbs free energy can be evaluated via the equilibrium constant of a reaction. In this
chapter, first the experimental approaches for equilibrium constant determination are
introduced, then high throughput screening which is used in drug discovery is briefly
presented. Computational methods such as virtual screening (docking) are introduced
and then the focus will be on the binding free energy calculation based on MD simulation.
Protein-protein interactions can be treated similarly to protein-ligand interactions, where
one protein takes the role of the ligand.
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3.1 Experimental Approaches
3.1.1 Experimental Determination of Binding Affinities
Numerous binding assays have been designed to determine binding affinities experimen-
tally. They can be classified into separation assays122 and direct assays123 according to
whether they require separation of the components for analysis. In most experiments,
the binding affinity is given as a dissociation constant Kd. For the aggregation of two
proteins P, one is considered as ligand L. Kd is thus defined as
P + L
Kd−−−−−−⇀↽ −
Ka
PL (3.1)
Keq = Ka = K
−1
d =
[PL]
[P][L]
(3.2)
where Keq is the equilibrium constant for the binding, Ka the association and Kd the
dissociation constant. The range of Kd values is very wide in protein-protein interactions,
ranging from Micromolar to Picomolar and resulting in free energy changes (∆G) of
−6 to −19 kcal/mol.3 [PL] is the concentration of the protein-protein complex and [P]
respectively [L] are the concentrations of the free proteins. Upon titration of a protein to
an excess concentration of another (see Figure 3.1), the free concentration of one protein,
the ligand, reaches the value of Kd when the receptor binding sites are half saturated
with ligand (see Figure 3.1). The value of Kd is the maximal specific binding, which is
equal to the half maximal inhibitory concentration (IC50).
The binding free energy (∆G) of the aggregation of two proteins can be calculated
from the equilibrium constant Keq.
∆Gbind = −RT lnKeq = ∆Hbind − T∆Sbind (3.3)
where R is the gas constant and T is the absolute temperature.
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Figure 3.1: This ligand binding graph displays the ratio of bound protein vs. the total
ligand concentration. The Kd is at the ligand concentration where 50% of
the ligand is bound.
The thermodynamics of ligand binding can be measured directly by Isothermal
titration calorimetry (ITC), one of the latest techniques to be used in characterizing
binding affinity of ligands for proteins. ITC can directly determine the binding free
energy ∆Gbind, the enthalpy changes ∆Hbind and the entropic component ∆Sbind.
3.1.2 High-throughput Screening
High-throughput screening124 is a drug-discovery process widely used in the pharmaceu-
tical industry. It utilizes robotics, data processing and control software, liquid handling
devices, and sensitive detectors to quickly assay the biological or biochemical activity of
large libraries of compounds, with easily thousands of molecules in a library. The goal is
to identify compounds that interact with the target protein and provide a starting point
for drug design. Usually, the results are organized in a list sorted according to activity
level, and a threshold value above which the compounds are considered active will be
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chosen for further analysis. These compounds are called hits. After hit identification,
the selected hits are tested in a new and more focused screening, i.e. testing the activity
based on the concentration of the compound and calculating the maximal inhibitory
concentration IC50. Assay hits which have well-behaved titration curves and IC50 values
of typically less than 10 µM are subjected to the next step studies, such as validation
assays and selectivity tests. This process is usually done manually with only a small
number of molecules to test.125
3.2 Computational Methods
3.2.1 Virtual Screening
To reduce the number of compounds that have to be synthesized and tested in HTS,
computational methods such as virtual screening are used. In virtual screening, molecules
form large libraries of available compounds are docked computationally into the binding
site of the protein target and their binding is evaluated.
To identify compounds that are potential drug leads, the binding energy between the
protein and compounds is calculated and those that have the most favorable interaction
are selected for further analysis. The drawback of such virtual screening methods is that
the algorithms currently used have to make a number of approximations in order to be
able to screen large numbers of compounds in a reasonable time, which results in less
accurate description of the binding energies. One way to overcome these limitations is to
use more accurate force field based methods to determine the binding energies of the
compounds and thereby more reliably reject those poses that don’t have a favorable
binding energy.
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3.2.2 Docking and Scoring
In molecular modeling, docking is a method which aims to predict the preferred orienta-
tion of one molecule to a second when bound to each other to form a stable complex.
Docking can be between protein/small ligand, protein/protein, protein/peptide, pro-
tein/nucleotide. In general, there are two aims of studies in high-throughput docking
which is used as a hit identification tool.126 The first one is to identify the ligands by
virtual screening (docking), including finding possible poses, and orientation of a ligand
to fit the active site of the macromolecular target. The second is to predict the binding
affinities of the binding modes (scoring). Docking is generally devised as a multi-step
process and begins with the application of docking algorithms that pose small molecules
in the active site. Algorithms are complemented by scoring functions which evaluate the
interactions between the compounds and the targets. The success of a docking program
depends on both components: the search algorithm and the scoring function.127
Protein Ligand Complex
+
Figure 3.2: Protein, ligand docking.
There are three categories of docking programs which are divided as: Random/stochastic
methods, systematic methods and simulation methods.126,128 Three types or classes of
scoring functions are currently applied: force field based, empirical and knowledge-based
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scoring functions (see Table 3.1).
Table 3.1: Types of flexible ligand-search methods and scoring functions, adapted from
Kitchen et.al.126
Types of flexible ligand-search methods Types of scoring functions
Random, stochastic Force-field-based
AutoDock129 AutoDock
GOLD130 GOLD
MOE-Dock131 D-Score
PRO LEADS132 G-Score
DOCK
Systematic Empirical
DOCK133 LUDI
FlexX134 F-Score
Glide135 ChemScore
Hammerhead136 SCORE
FLOG137 Fresno
X-SCORE
Simulation Knowledge-based
DOCK PMF
Glide DrugScore
MOE-Dock SMoG
AutoDock
Hammerhead
There is a need for fast, accurate and reliable methods to calculate the binding
affinity of ligands to a protein.138 The methods ideally should help drug discovery by
pre-screening the potential drugs so that we can reduce the number of compounds that
need to be synthesized for experimental screening. The aim of most docking programs
is to screen huge number of structures within a relatively short time. To achieve this
goal, numerous approximations are applied to obtain a reasonable ranking of compounds,
rather than calculate absolute binding affinities accurately. On the other hand, more
elaborate simulation methods such as Monte Carlo or Molecular Dynamics can get more
accuracy with conformational sampling, but are more computationally intensive and not
applicable to high-throughput virtual screening.139 In the section below a number of
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methods that are used to calculate binding affinities between protein and ligands/protein
are described briefly.
3.2.3 Molecular Mechanics Methods
The free energies of molecular systems can describe their tendencies to associate and react.
In rational drug design, to reach the required affinity and specificity, accurate estimates
for both structure and binding energy are needed but unfortunately are still lacking at
present.139 Estimating binding free energies accurately is a very time-consuming process.
Low-throughput computational approaches for the calculation of ligand binding free
energies can be divided into “pathway” and “endpoint” methods. In pathway methods,
the system is converted from one state (e.g., the complex) to the other (e.g., the un-
bound protein/ligand). This can be yielded by introducing a set of finite or infinitesimal
“alchemical” changes to the energy function (the Hamiltonian) of the system through Free
Energy Perturbation (FEP) or Thermodynamic Integration (TI), respectively. Currently,
using methods such as FEP and TI combined with atomistic molecular dynamics (MD)
or Monte Carlo (MC) simulations in explicit water solvent models, can obtain the most
accurate results. Similar results with lower computational cost can be obtained with
methods such as MM-GBSA/MM-PBSA or Linear Interaction Energy. All of the methods
are still regarded as computationally too expensive to be broadly used in virtual screening.
Thermodynamic Integration
The aim of thermodynamic integration is to compute the difference in a thermodynamic
property (usually the free energy) of the system between some reference state and the
state of interest. This is done via sampling of state configurations in Molecular Dynamics
or Metropolis Monte Carlo simulations. The free energy difference between two states
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cannot be calculated directly, because the free energy of a system is not simply a function
of the phase space coordinates of the system, but instead, is related to the canonical
partition function Q(N,V,T). To measure the free energy change from initial to final state,
thermodynamic parameters representative for the system are changed infinitesimally
slowly in an effort to let the system equilibrate at each stage along the path, so that the
path can be considered as reversible. The free energy difference is then calculated by
defining a thermodynamic path between the states and integrating over enthalpy changes
along the path. In addition to the thermodynamic variables such as volume, pressure,
temperature, in a molecular simulation, one can change the interaction potential of the
system and introduce suitable external potentials, to provide a larger variety of reversible
paths and reference states.140 For a reaction, A → B, a variable λ is introduced, which is
0 for A (reactant) and 1 for B (product). Then, the potential energy of the system can
be written as
U(r1, . . . , rN , λ) = f(λ)UA(r1, . . . , rN ) + g(λ)UB(r1, . . . , rN ) (3.4)
For simplicity, f(λ) = 1− λ and g(λ) = λ can be used. As we have
U(λ) = (1− λ)UA + λUB, (3.5)
we obtain
∂U(λ)
∂λ
= UB − UA. (3.6)
U is decomposed into solvent-solvent interactions (ww) and solute-solvent interactions
(ow) in the case of solvation free energy and we get UA = Uww and UB = Uww + Uow. So
we have
∂U(λ)
∂λ
= Uow = U
vdW
ow + U
es
ow, (3.7)
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where UvdWow is the solute-solvent van der Waals interaction and U
es
ow is the solute-solvent
electrostatic interaction. Therefore, we have to calculate 〈Uow〉λ for different λ values
between 0 and 1 to evaluate the thermodynamic integral, where 〈· · · 〉λ is the average
from the simulations performed at a particular value of λ.
Free Energy Perturbation
Free energy perturbation methods (FEP) and thermodynamic integration are often
referred as computational alchemy. Compared to a number of approaches used for
computing ligand-protein binding affinities with use of empirical models, and a model141
that treats part of the system as a continuum,142–144 molecular dynamics simulations in
full atomic detail employed with the FEP methodology offer the prospect of a generally
applicable rigorous “first principles” a solution to the “binding problem”.145 The FEP
methodology has usually been used to compute ∆∆Gbind, differences between the binding
free energies of two similar ligands to one protein target, or of one ligand to a protein
and its mutant.
P + L1
∆Gbind(L1)−−−−−−−→ PL1y
y∆∆GmutL
y∆∆GmutPL
P + L2 −−−−−−−→
∆Gbind(L2)
PL2
These methods generally give very good results for the binding energy, with errors less
than 1 kcal/mol.146,147
〈∆G〉(A→ B) = GB −GA = −kBT ln〈exp(−EB − EA
kBT
)〉A (3.8)
aIn physics, when a calculation starts directly at the level of established laws of physics and does not
make assumptions such as empirical model and fitting parameters, it is said to be from first principles.
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where T is the temperature, kB is Boltzmann’s constant, the triangular brackets show an
average over a simulation run for state A. In practice, one runs a normal simulation for
state A, but the energy for state B is also computed. Free energy perturbation calculations
only converge properly when the difference between the two states is small enough. So
it is usually necessary to divide a perturbation into a series of smaller “windows” and
compute independently.
MM-PBSA and MM-GBSA
The MM-PBSA/GBSA approach represents the post-processing end-state method to
evaluate free energies of binding or to calculate absolute free energies of molecules in
solution. The MM-PBSA/MM-GBSA approach employs molecular mechanics, the Poisson
Boltzmann model respectively the Generalized Born model and solvent accessibility
method to obtain energies from structural information circumventing the computational
complexity of free energy simulations. In these approaches, a thermodynamic cycle is
considered as follows:
in vacuo: P + L
∆G0bind−−−−→ PLy∆GPsolv
y∆GLsolv
y∆GPLsolv
in solution: Psolv + Lsolv −−−−→
∆Gbind
PLsolv
The binding free energy is estimated as the sum of contributions from gas phase (“vacuo”)
binding and solvation free energies that arise from the gas phase to water transition:
∆Gbind = ∆G
0
bind + ∆G
PL
solv −∆GPsolv −∆GLsolv (3.9)
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The binding free energies are calculated for many snapshots from a molecular dynamics
simulation and averaged to yield the final energies.
Gas Phase Contribution The gas-phase contribution to the binding free energy (∆G0bind)
is calculated according to
∆G0bind = ∆Hgas − T∆Sgas (3.10)
These parts are calculated using molecular mechanics. ∆Hgas = ∆E
0
bind = ∆EMM is
calculated from the sum of the internal, the van der Waals and the electrostatic interaction
energies between the two monomers
〈∆E0bind〉 = 〈∆Eintra〉+ 〈EvdW〉+ 〈Eelec〉 (3.11)
where 〈∆Eintra〉 is the difference in the internal energy and
〈∆EXintra〉 = 〈∆EXintra,bond〉+ 〈∆EXintra,vdW〉+ 〈∆EXintra,elec〉 (3.12)
〈∆EXintra,bond〉, 〈∆EXintra,vdW〉 and 〈∆EXintra,elec〉 are the energy of the bonded terms (bonds,
angles, dihedral angles and improper angles) for a given molecule X, and the van der
Waals and electrostatic interactions between the atoms of this molecule, respectively.
〈∆Eintra〉, 〈EvdW〉, 〈Eelec〉 terms can be calculated according to the CHARMM molec-
ular mechanics force field, with a dielectric constant of 1 and no cutoff for nonbonded
interactions.
Entropy Contribution The entropy contribution can be decomposed into translational
〈∆Strans〉, rotational 〈∆Srot〉, and vibrational contributions 〈∆Svib〉:
−T 〈∆S〉 = −T 〈∆Svib〉 − T 〈∆Strans〉 − T 〈∆Srot〉 (3.13)
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Strans and Srot are functions of the mass and moments of inertia, whereas calculation of
Svib is according to the quantum formula from a normal mode analysis
148. The force
constant matrix which is used to determine the normal mode vectors and frequencies can
be calculated and diagonalized by the VIBRAN normal mode module in the CHARMM
program.
The equations for the translational, rotational and vibrational contributions to
the free energy in the gas phase are as below, translations and rotations are treated
semi-classically and vibrations are treated quantum-mechanically.
A(trans) =
3
2
kBT −
[
5
2
+
3
2
ln
(
2pimkBT
h2
)
− ln(ρ)
]
kBT (3.14)
A(rot) =
3
2
kBT −
[
3
2
+
1
2
ln(piIAIBIC) +
3
2
ln
(
8pi2kBT
h2
)
− ln(σ)
]
kBT (3.15)
A(vib) =
3N−6∑
i=1

12hνi + hνi
e
hνi
kBT − 1
−
 hνi
e
hνi
kBT − 1
− kBT ln(1− e
−hνi
kBT )

 (3.16)
where m is the mass, ρ is the number density (corresponding to the standard state, which
equal to 1M here), IAIBIC is the product of the 3 principal moments of inertia, σ is the
symmetry factor (1 for non-symmetric molecules, 2 for the effectively symmetric dimer
between 2 non-symmetric monomers), N is the number of atoms, h is the Planck constant,
and νi is the frequency of the i th internal normal mode. The enthalpic contribution
from translational and rotational degrees of freedom is a small constant (1.5 kBT , which
is 0.9 kcal/mol at 300K, for translations and an equal amount for rotations), the entropic
contribution increases with the logarithm of the size of the molecule as they are dependent
on mass and principal moments of inertia according to Eq. 3.14. It is accepted that using
gas-phase equations to study the translational, rotational and vibrational properties
of molecules in solution is a reasonable approximation.62,149–151 It has been previously
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shown that the influence of Svib on relative binding free energies ∆∆G is in general small
and does not affect the ranking of ligands.46,152–154
Solvation Contribution The solvation contributions 〈GPsolv〉, 〈GLsolv〉 and 〈GPLsolv〉 consist
of contributions from electrostatics and non-polar interactions
〈Gsolv〉 = 〈Gelec〉+ 〈Gnonpolar〉 (3.17)
In MM-PBSA, the electrostatic contribution to the solvation term is calculated by
solving the Poisson-Boltzmann (PB) equation.155,156 The Poisson-Boltzmann equation
(PB) describes the electrostatic environment of a solute in a solvent containing ions.
~∇[(~r)~∇Ψ(~r)] = −ρf (~r)−
∑
i
c∞i ziqλ(~r)exp
[−ziqΨ(~r)
kBT
]
(3.18)
where ~∇ is the divergence operator, (~r) is the position-dependent dielectric, ~∇Ψ(~r) is the
gradient of the electrostatic potential, ρf (~r) represents the charge density of the solute,
c∞i represents the concentration of the ion i at a distance of infinity from the solute, zi is
the charge of the ion, q is the elementary charge, kB is the Boltzmann constant, T is the
temperature, and λ(~r) is a factor for the accessibility of position r to the ions in solution
(often set to uniformly 1). The equation can be linearized to be solved more efficiently.157
The Generalized Born (GB) model used in MM-GBSA is an approximation to the
exact linearized Poisson-Boltzmann equation. In the GB model, the protein is treated as
a set of spheres whose internal dielectric constant differs from the external solvent.158
GGB =
1
8pi
(
1
0 − 1
)
N∑
i,j
qiqj
fGB
(3.19)
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where
fGB =
√
r2ij + a
2
ije
−D (3.20)
where D =
(
rij
2aij
)
, and aij =
√
aiaj . 0 is the permittivity of free space,  is the dielectric
constant of the solvent. qi is the electrostatic charge of particle i, rij is the distance
between particles i and j, and ai is the effective Born radius which can be thought as
the distance from the atom to the molecular surface. It is very important to estimate
accurately the effective born radii for the GB model.
GBSA is one of the most commonly used implicit solvent model combinations which
is a Generalized Born model with a hydrophobic solvent accessible surface area SA term.
The nonpolar contribution is the sum of a solvent-solvent cavity term and a solute-solvent
van der Waals term
Gcav +GvdW =
∑
σkSAk (3.21)
where SAk is the total solvent-accessible surface area (SASA) of atoms of type k and σk
is an empirical atomic solvation parameter, with a value of 0.0072 kcal/mol/ A˚
2
. The
electrostatic contribution to the solvation energy in MM-GBSA is calculated within the
generalized Born approximation
Gpol = −166
(
1− 1

)∑∑ qiqj
fGB
(3.22)
where  is the dielectric constant of water ( = 80), qi and qj are the charges of atoms
i and j. fGB is an expression that depends on the Born atomic radii αi and αi and
distances rij .
159
fGB = r
2
ij + αiαj exp
(
−r2ij
8αiαj
)
(3.23)
To sum up, 〈∆G0bind〉 is the gas-phase term obtained by molecular mechanics cal-
culations MM, 〈Gelec〉 can be determined using the Poisson-Boltzmann or Generalized
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Born (PB/GB) implicit solvent model, 〈Gnonpolar〉 is assumed to be proportional to the
solvent accessible surface area (SASA), the mehods are called: MM-PB/GBSA. After
averaging the energy terms, the binding free energy can be expressed as follows:
〈∆Gbind〉 = 〈∆Eintra〉+ 〈∆EvdW〉+ 〈∆Eelec〉+ 〈∆Gelec,desolv〉+ 〈∆Gnp,desolv〉 − T 〈∆S〉
(3.24)
Decomposition of Binding Free Energy MM-GBSA allows to easily decompose the
binding free energy at the atomic level (with the exception of the contribution of the
entropy terms), which can be used to evaluate the contribution of each residue to the total
binding free energy as well as the contribution of its side-chain and backbone. From Eq.
3.24, for the same trajectory method (STM), 〈∆Eintra〉 is equal to zero, as the internal
energies of the complex and the individual one are calculated from the same trajectory.
In this thesis, we used STM which has also been employed by others,160–162 and it has
been shown to provide reasonable results. In the different trajectory method (DTM),
the 〈∆Eintra〉 term is important, 〈∆EXintra,vdW 〉 and 〈∆EXintra,bond〉 can be calculated in
the same way as 〈∆EXvdW 〉 and 〈∆EXbond〉. For the dimerization free energy, in principle,
using separate trajectories for the monomers and dimer can capture the conformational
changes upon binding, but the results will be very sensitive to the detailed structures.
Furthermore, the DTM introduces additional errors compared to the STM.46 For electro-
static interaction energy between the 2 monomers, the contribution of atom i is given
by
〈Eielec〉 =
1
2
∑
j
qiqj
rij
(3.25)
where j belongs to monomer I, and i belongs to the other. ri,j is the distance between
the two atoms with charge qi and qj , respectively. The SASA of each atom in the dimer
is SASAi, and the contribution to the non-polar term 〈∆Ginp,solv〉 = σ × [SASAi,d −
(SASAi,m1 + SASAi,m2)]. The GB-MV2 model159,163 uses the following expression for
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the electrostatic solvation energy term
〈∆Gelec,solv〉 = −166.0(−1solute − −1solvent)
∑
i,j
qiqj√
r2ij + aiajexp(
−r2ij
Ksaiaj
)
(3.26)
where solute and solvent are the dielectric constant of the solute and the solvent, in this
thesis we used the value of 1 and 80, respectively. ai and aj are the Born radii of atoms i
and j. In the GB-MV2 model, the value of Ks is 8 instead of 4 as in the Still equation.
158
Therefore, the contribution of atom i to 〈Gelec,solv〉
〈∆Gielec,solv〉 =− 166.0(−1solute − −1solvent)
q2i
ai
− 1
2
166.0(−1solute − −1solvent)
∑
j 6=i
qiqj√√√√r2ij + aiajexp
(
−r2ij
Ksaiaj
) (3.27)
Compared to the PB approach, GB is much faster and can allow one to decompose
easily and rapidly the electrostatic solvation energy and thus, the binding free energy,
into atomic contributions from only 1 calculation. The per-atom contributions can be
summed up to atomic groups such as residues, backbones, and sidechains, to obtain their
contributions to total binding free energy. A decomposition of the binding free energy in
the PB calculations is also possible82,164 but requires separate and time-consuming calcu-
lations. The results obtained by using the GB-MV II model are very close to the solvation
free energies calculated by solving the PB equation.155 The MM-PB/GBSA approach
has been applied to estimate the binding energy for protein-protein and protein-ligand
systems.165–167 It has also been used to predict the effect of residue mutations on the
binding energy of protein-protein systems with the “computational alanine scanning”160
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Limitations of MM-GB/PBSA Calculations MM-GB/PBSA methods are valuable
tools used in computer-aided drug design. However, as with any other method, they have
limitations which have to be taken into consideration when they are employed. First,
they are useful for ranking relative ligand binding affinities, but not accurate enough
for absolute binding free energy predictions.168 PB and GB results strongly rely on
atomic charges and van der Waals radii, which are often optimized for MD simulations.
The molecular structure of the solvent was not considered by continuum electrostatics
models, which may affect the result, particularly when key receptor-ligand interactions
are bridged by water molecules, as we found in this thesis. Furthermore, the inclusion of
entropic contributions make the results closer to experimental absolute affinities138, but it
is time consuming to calculate the entropic terms and also contains a lot of uncertainties.
Moreover, the value of the protein/ligand dielectric constant is chosen empirically, Hou
et.al,154 suggested =4 for a lightly charged protein-ligand binding interface, =2 for a
moderately charged binding interface and =1 for a hydrophobic binding interface may
improve ligand ranking.
While molecular docking algorithms are computationally efficient methods for screen-
ing a large number of ligands against a targeted protein in a reasonable time, it is still
not very practical to generate MD ensembles for more than certain number of receptor-
ligand structures in a MM-GB/PBSA calculation. However, MM-GB/PBSA can serve
well as a post-docking method in virtual screening experiments. Using MM-GB/PBSA
algorithms on single docking poses is proven to improve correlations between predicted
and experimental binding affinities.169–171 Post-docking MM-GBSA is implemented in
the Schroedinger software in the program Prime, and the entropy term is neglected by
default. Manta et al. extended MM-PBSA by exploiting quantum mechanics methods in
QM/MM-PBSA172,173, where a hybrid gas phase energy term (EQM/MM ) replaces the
pure molecular mechanics energy EMM in Eq. 3.11. While this method can eliminate
the problem arising from deficient ligand forcefield parameters, it is significantly more
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expensive than MM-GB/PBSA, and therefore of limited viability.
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Cyclic diguanosine-monophosphate (c-di-GMP, CDG) is a bacterial signaling molecule
that triggers a switch from motile to sessile bacterial lifestyles.174,175 It has attracted
considerable attention from different fields since it was discovered 20 years ago.89,174–183
Extensive research on the small signaling molecule cyclic diguanosine monophosphate
(c-di-GMP) has highlighted its critical regulator role in bacterial metabolism. c-di-GMP
is produced from two molecules of GTP by the activity of diguanylate cyclases (DGCs)
which usually contain a conserved GGDEF (Gly-Gly-Asp-Glu-Phe) domain. c-di-GMP
can also bind to some DGC proteins, repressing the activity of DGC via allosteric
changes.4,184 On the other hand, c-di-GMP is degraded by specific phosphodiesterase
(PDE) into 5’-phosphoguanylyl-(3’-5’)-guanosine (pGpG); pGpG is subsequently split
into two GMP molecules. The latter enzyme usually has a conserved EAL domain (a
domain enriched in Glu-Ala-Leu). In some bacteria, the HD-GYP domain (His-Asp,
Gly-Tyr-Pro) replaces the EAL domain.
Most GGDEF and EAL (or HY-GYP) domains are linked to a signal input (or
sensory) domains such as the PAS (oxygen sensing), blue light sensing, red/far red light
sensing (GAP-PHY domain), gas sensing (haemerythrin), REC (phospho receiver) and
GAF domains. Afterwards, through the interaction with different receptors, such as
transcription factors, a Riboswitch or a PilZ domain185–187, c-di-GMP modulates diverse
biological functions, such as biofilm formations, motility, virulence or the cell cycle. It
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has been characterized that c-di-GMP negatively modulates cell motility and traits
associated with bacterial virulence and stimulates several biofilm-associated functions.188
High concentrations of c-di-GMP promote sessile growth (biofilm formation), while low
concentrations of c-di-GMP promote motile growth.
The discovery that most bacteria use c-di-GMP as a ubiquitous second messenger
to orchestrate the switch between a planktonic and a sedentary, biofilm-related lifestyle
established an entirely new field of research for studying the cellular, molecular and
structural details of the components involved in this process.174 The first example of this
regulatory network was characterized in G. xylinus (see Figure 4.1).189,190 The proteins
are involved in c-di-GMP synthesis and degradation through three domains, a PAS, a
GGDEF and an EAL domain. Oxygen is the first messenger that binds to the PAS
domain, which has a heme or flavin binding pocket and serves as an oxygen or redox
sensing domain. c-di-GMP is the second messenger. The PDE activity (EAL domain)
is tightly coupled to the binding status of heme in the PAS domain. Under aerobic
conditions, O2 binds to PAS-heme, PDE activity is diminished and c-di-GMP levels are
high which promotes its binding to downstream cellulose synthase to invoke an allosteric
change and produce cellulose. On the other hand, under anaerobic conditions (no oxygen
binding to PAS-heme), PDE activity is restored and c-di-GMP concentration diminishes,
resulting in the removal of the cellulose synthase activity.190,191
Inhibition by Domain Immobilization The GGDEF domain was first identified in PleD
in the aquatic bacterium Caulobacter crescentus. PleD4,184,192,192–197 contains three
domains, with a REC1-REC2-GGDEF domain organization. REC1 and REC2 are
phosphorylation receiver domains connected by a loop. Phosphorylation of REC1-REC2
triggers PleD to dimerize.190 In non-phosphorylated PleD (pdb code: 1W254) and phos-
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Figure 4.1: Regulation of cellulose synthesis in G. xylinus under anaerobic (a) and aerobic
(b) conditions. Under anaerobic conditions, PDE is fully functional, leading
to the degradation of c-di-GMP. Under aerobic conditions, PDE activity is
repressed. Accumulated c-di-GMP leads to the activation of cellulose synthase.
Adapted from190
phorylated PleD (pdb code: 2WB4198), structure determination identified an allosteric
site for the mutually intercalated c-di-GMP dimer [c-di-GMP]2. Binding of a c-di-GMP
dimer to this allosteric site (inhibition site, I-site) via residues R539, D362 and R390
on the DGC domain (pdb code:1W25), leads to strong non-competitive inhibition of
PleD.4,196 Moreover, c-di-GMP present in the I-site crosslinks to either the neighboring
D2 domain via interaction to R148, R178, or to another neighboring DGC domain via
interactions to R313.4,184 A mechanistic model by Jenal et al.4,184 suggested that binding
c-di-GMP dimer in the I-site locks the DGC domain in a non-productive orientation
which blocks the encounter of two GTP-loaded active site (A-site) and subsequent the
generation of c-di-GMP monomer. Two different immobilization modes are found, named
DGC-D2 and DGC-DGC crosslinking (Figure 4.2)
Subsequent studies has confirmed that product inhibition is a general feature of
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DGCs (GGDEF domain)196. When c-di-GMP concentration reaches a threshold, with
a Ki of 0.5 µM, product inhibition, inactivates the DGC enzyme. However, the nature
of communication between I- and A- site for self-regulation is still unknown. Several
aspects of this signaling molecule remain far from being understood. When c-di-GMP
binds to PleD I-site, does it bind as a monomer and then forms dimer or two c-di-
GMP monomers form the dimer first, and bind to protein as a dimeric form? In this
chapter, we present our results from the all-atom computational simulations to study
the structure and energetic of the c-di-GMP dimer and analog in the solution and proteins.
4.1 Stability and Dynamics of Cyclic Diguanylic Acid in
Solution
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Figure 4.2: Mechanistic model of PleD regulation. The model is adapted from Chan et
al.4. The DGC domain (green) is connected via a flexible linker to the stem
(receiver domain D1 [red] and adaptor domain D2 [yellow]) and is supposed
to be mobile relative to it. (Upper row) Activation. Phosphorylation of
domain D1 leads to a rearrangement of the stem domains, which, in turn,
allows for formation of a tight dimeric stem (3). The dimeric arrangement is
a prerequisite for an efficient and productive encounter of the two substrate-
loaded DGC domains to form the c-di-GMP product (4). (Lower row)
Product inhibition. Dimeric product molecules, (c-di-GMP)2, can crosslink
the primary inhibition site on DGC, Ip, with a secondary binding site either
on D2, Is,D2 (5) or on the adjacent DGC domain, Is,DGC (6). The former
structure has been observed experimentally with nonactivated PleD, the latter
structure is presented in this report. In both cases, the DGC domains become
immobilized, and the active sites are hampered from a productive encounter.
Note that a possible direct communication between Ip and A sites (Christen
et al., 2006) is not depicted. Reprint184 with permission of Elsevier.
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Stability and Dynamics of Cyclic Diguanylic Acid in
Solution
Lixian Zhang and Markus Meuwly*[a]
1. Introduction
Cyclic diguanylic acid (cyclic diguanosine monophosphate,
c-di-GMP, CDG) is an important second messenger in bacteria,
primarily involved in signaling the switch between a motile
(planctonic) and a sessile (biofilm-related) lifestyle.[1–3] CDG-de-
pendent signaling in bacteria is a complex process in which a
multitude of diguanylate cyclases and phosphodiesterases are
involved, even in a single bacterial species. The molecule con-
sists of two guanosine monophosphate (GMP) moieties linked
by two phosphodiester bonds. Cyclic dinucleotides in solution
tend to form multimeric structures. The X-ray structure of CDG
was found to consist of a Mg2+-bound dimer,[4] but higher oli-
gomeric states were proposed and found in solution depend-
ing on the type and concentration of the cation used and the
local concentration of CDG.[5] Other arrangements, such as a
tetrameric form with a central cavity, were proposed but not
observed in the crystal structure.[6,7]
Of particular importance for the in vivo situation and in vitro
characterization is the question whether CDG in solution
occurs in monomeric or dimeric form. This is relevant to better
understanding molecular mechanisms underlying interaction
of CDG with proteins or RNA. Experiments with the protein
PleD from Caulobacter crescentus, a protein that efficiently cat-
alyzes the conversion of GTP to c-di-GMP,[8] showed that in the
protein inhibition site (I site) the second messenger binds as a
metal-free dimer,[9] as did a crystal structure of the diguanylate
cyclase WspR.[10] In addition to the metal-free dimer, the X-ray
structure of PleD also contains CDG monomers in the active
site (A site). Contrary to that, the crystal structure of Vibrio
cholera VCA0042 protein, consisting of YcgR-N and PilZ do-
mains, shows that CDG binds in its monomeric form,[11] where-
as in PP4397 of Pseudomonas putida, which also has YcgR-N
and PilZ domains, the CDG dimer binds.[12]
For understanding the interaction of PleD,[9] WspR,[10] and
other proteins with CDG, the aggregation state of the messen-
ger in solution is of fundamental interest. Several scenarios can
be imagined: 1) CDG is synthesized in its metal-bound form
and released to the solvent, where it loses Mg2+ and binds as
a metal-free dimer. 2) After synthesis the Mg2+-bound dimer
dissociates into its monomeric form and binds sequentially as
two separate monomers. 3) The metal-free dimer is also stable
in solution and binds in this form. Experiments in solution
found that CDG exists in five distinct but related complexes.[5]
The methods employed (UV and CD spectroscopy) could estab-
lish guanine stacking, which also occurs in the crystal struc-
tures, and NMR spectroscopy showed that different oligomeri-
zation states occur in solution with different propensity de-
pending on the chemical identity of the cation and its concen-
tration. However, no structural data in solution is yet available.
In the following we determine the stability and dynamics of
solvated metal-free and metal-bound CDG from atomistic sim-
ulations and electronic structure calculations.
Methods Section
Electronic Structure and Molecular Dynamics Simulations: Density
functional theory (DFT) calculations were carried out with Gauss-
ian 03[13] at the B3LYP/6-31G** level. The starting structures for the
CDG monomer and dimer (see Figure 1a and b) were those found
in the X-ray structure of PleD[9] (code 1W25, Brookhaven Protein
Data Bank (PDB)[14]). For the Mg2+-bound CDG dimer (Figure 1c)
coordinates from the Cambridge Structural Database[4,15] were
used. The overall charge is 4 for the mutually intercalated CDG
dimer and 2 for the Mg2+-bound dimer.
Cyclic diguanylic acid (CDG) is a ubiquitous messenger in-
volved in bacterial signaling networks. Despite its central role
in motility, biofilm formation, virulence, and flagellum develop-
ment, fundamental properties such as its aggregation state are
still poorly understood. Here the dynamics and stability of
metal-free and Mg2+-bound CDG are characterized. Atomistic
simulations establish that the CDG dimer is slightly favored (by
5 kcalmol1) over its dissociated form (2CDG), while the
Mg2+ ion coordinated in the X-ray structure readily dissociates
from (CDG)2 in solution and prefers water coordination. As a
ligand in a protein, CDG binds both as a U-shaped and a quasi-
linear monomer. The current results indicate that the energy
difference between these two conformations is only a few kilo-
calories per mole, which explains the facile adaptation to dif-
ferent protein environments. This, together with the slight
preference of (CDG)2 over 2CDG suggests that (CDG)2 binding
to a protein does probably not occur via sequential binding of
two individual monomers.
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Department of Chemistry, University of Basel
Basel (Switzerland)
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All molecular dynamics (MD) simulations were carried out with the
CHARMM program[16] using the CHARMM27 force field[17] with peri-
odic boundary conditions (PBC). Force-field parameters for CDG
were those determined and used previously.[18,19] The structures of
metal-free and Mg2+-bound CDG dimer were optimized with 5000
steps of steepest descent minimization followed by adopted
Newton–Raphson minimization until a gradient of 107 was
reached. Then the two complexes were solvated in a pre-equili-
brated water box containing 1452 TIP3P[20] water molecules of di-
mension 37.334.134.1 3. The solvent was optimized and equili-
brated at 300 K for 30 ps in the presence of the fixed solute. Final-
ly, the structures of the solutes were relaxed by means of 2000
steps of steepest descent minimization. The two systems, with a
total of 4261 and 4283 atoms, respectively, were gradually heated
to 300 K for 15 ps followed by 100 ps of equilibration. All MD simu-
lations were carried out by using SHAKE[21] to constrain all bonds
involving hydrogen atoms. For metal-free and metal-bound CDG
dimer five independent trajectories (100 ns in total) and two inde-
pendent trajectories (20 ns in total) were run, respectively.
During the MD simulation, the CDG dimer was restrained to the
center of the water box by applying a weak harmonic potential to
the center of mass of the CDG dimer with a force constant of
0.1 kcalmol12 to avoid translation of the solute within the peri-
odic box. To follow overall structural changes, root mean square
deviations (RMSDs) were calculated along the trajectories. For sim-
ulations of the Mg2+-bound CDG dimer it was observed that the
metal has a finite probability to escape to the solvent on the time-
scale of the simulations (10 ns). Therefore, additional simulations
were carried out in which the position of the magnesium ion was
constrained relative to the N7 nitrogen atoms of the central gua-
nosine unit by using NOE constraints. The energy biases added to
the system are E ¼ 0:5KminðR RminÞ2 for R<Rmin and
E ¼ 0:5KmaxðRmax  RÞ2 for Rmax<R<Rmin. In all simulations,
Rmin ¼ 2:0, Rlim ¼ 4:9, and Rmax ¼ 2:9  were used. The force con-
stants ½Kmin; Kmax included [100,200] and [500,1000] kcalmol12,
respectively. Alternatively, to avoid biasing the simulations, en-
hanced charges on the two N7 atoms were used. More precisely,
the following charge combinations were used for N7, C8, C5, C4,
and H10 (see Figure 1d): model I (0.60, 0.25, 0.00, 0.26, 0.16),
model II (0.80, 0.30, 0.10, 0.29, 0.18), and model III (0.90, 0.37,
0.12, 0.29, 0.19), where model I is the original parameterization.
Free Energy of Dimerization: The binding free energy DG consists
of an enthalpic (DE) and an entropic contribution (DS), which can
be calculated according to a thermodynamic cycle.[22, 23] Here the
molecular mechanics with generalized Born surface area (MM-
GBSA) approach[24] is used, which decomposes the binding free
energy DGbind into a sum of the gas-phase contribution, the desol-
vation energy of the system upon binding DGdesolv, and an entropic
contribution TDS [Eq. (1)]:
DGbind ¼ DG0bind
 þ DGdesolvh i  T DSh i ð1Þ
The brackets indicate averages of the individual terms along an
equilibrium MD simulation.[25] The gas-phase contribution DG0bind
 
consists of the difference in van der Waals (vdW) and electrostatic
energies between the dimer (D) and the individual monomers (M),
whereas the desolvation (desolv) term consists of a nonpolar (np)
contribution, which is assumed to be proportional to the solvent-
accessible surface area (SASA), and an electrostatic (ele) contribu-
tion calculated with the GB-MV2 model.[26, 27] A value of
0.0072 kcalmol12 was used to relate the buried SASA to the
nonpolar desolvation free energy:[28,29, 25]
DGbind ¼ DG0bind
 þ DGdesolvh i  T DSh i
¼ DEintrah i þ DEvdWh i þ DEelech i þ DGele;desolv
 þ DGnp;desolv
  T DSh i
ð2Þ
The energies calculated for snapshots taken every 10 ps by using
the ’’same trajectory method’’ (STM)[25] were averaged over 10 ns.
In the STM, the energy terms relative to the isolated monomers
are calculated by using coordinates taken from the simulation of
the dimer. The entropy term is partitioned into translational, rota-
tional, and vibrational terms following standard equations of statis-
tical mechanics.[30] The translational contribution only depends on
the mass of the system and the rotational part is related to the
moments of inertia. The vibrational part can be calculated from
the normal modes (NM) vi [Eq. (3)]:
TDSi ¼
hvi
e
hvi
kBT  1
 kBT lnð1 e
hvi
kBTÞ ð3Þ
where kB is the Boltzmann constant, h the Planck constant, and T=
300 K. The VIBRAN module of the CHARMM program was used to
calculate and diagonalize the force constant matrix to determine
the normal-mode vectors and frequencies. Normal modes were cal-
culated both for the fully minimized structures of the dimer and
the monomers in vacuo with a distance dependent dielectric (e=
Figure 1. Optimized geometry of : a) CDG monomer, b) CDG dimer, c) CDG
dimer with Mg2+ and four water molecules from ab initio calculation, and
d) labeled atoms for which charges were increased in the central guanosine
base part (electrostatic models I, II, and III).
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4), and a cutoff of 12  for non-
bonded interactions was applied.
The snapshots were minimized by
using the adopted basis Newton–
Raphson (ABNR) method until a
gradient of 107 was reached. All
reported values are averaged over
1000 frames, equally distributed
over the 10 ns trajectories.
2. Results and
Discussion
2.1. Electronic-Structure
Calculations
DFT calculations were carried out
for the isolated monomer, for
the CDG dimer, and for the CDG
dimer with hydrated Mg2+
(Mg2+(H2O)4) bound to it. For all
three systems the structure was
fully optimized starting from the
coordinates mentioned in the
Methods Section. The final RMSD
between the initial and opti-
mized structures is 0.86, 3.21,
0.34  for CDG monomer, CDG
dimer, and CDG dimer with hy-
drated Mg2+ , respectively. The rather large RMSD for the CDG
dimer is related to the overall charge of 4, which is not
shielded in a vacuum calculation. The RMSD for the individual
monomers of optimized CDG dimer are 2.10 and 2.17 , re-
spectively, and a Mg2+-free structure in solution is not avail-
able, which makes direct comparison difficult. On the other
hand, the agreement for the monomer and the Mg2+-bound
dimer is encouraging.
The stabilization energy of the dimer with respect to the
asymptotes (either the two monomers in the dimer configura-
tion EdimerM1 and E
dimer
M2 or the optimized, isolated monomer E
opt
M )
is DE1 ¼ Edimer  EdimerM1 þ EdimerM2
  ¼ 21:8 kcalmol1 or
DE2 ¼ Edimer  2 Eopt;M ¼ 18:2 kcalmol1, respectively (see
Table 1). Thus, in vacuum the metal-free dimer is destabilized
by about 20 kcalmol1. Solvation will, however, affect this due
to shielding of the charges. Thus, the energies of all optimized
structures were also calculated with the implicit polarizable
continuum model (PCM)[31] and the resulting binding energies
are DE1 ¼ 26:4 kcalmol1 and DE2 ¼ 27:8 kcalmol1, re-
spectively. For the Mg2+-bound dimer in all cases a stable
system was found. Additional calculations on the optimized
B3LYP/6-31G** structures were carried out to assess effects of
basis set superposition error (BSSE),[32,33] larger basis sets
[6-311++G(2d,2p)] , and a different functional (PBE1PBE).[34]
Conventional (Boys–Bernardi) BSSE correction[32] leads to slight-
ly decreased stabilization, whereas a more recent counterpoise
scheme[33] reduces the stabilization of the metal-free dimer in
vacuum considerably. With a much larger basis set, also a de-
stabilization of 11 kcalmol1 is found, whereas a calculation
with the 6-311++G(2d,2p) basis and the more recent
PBE1PBE functional yields a similar stabilization to B3LYP/6-
31**. The PBE1PBE functional was recently found to perform
best for describing nonbonded interactions, in particular H-
bonding.[35] Including solvation effects in all cases increases the
interaction energies and, with the exception of one of the
counterpoise schemes, leads to a stable dimer. The same con-
siderations were applied to the metal-bound dimer, and in all
cases increased stabilization compared to the metal-free dimer
was found.
2.2. Molecular Dynamics Simulations
With molecular dynamics simulations it is possible to account
for solvation effects beyond the approximation of implicit sol-
vents. Furthermore, the influence of entropic effects can be es-
timated and assessed. Following the methods outlined above
the dynamics of metal-free and metal-bound CDG dimer was
investigated in separate simulations. First, simulations of the
metal-free form are described.
Figure 2 shows the RMSD from the X-ray structure, calculat-
ed for the entire dimer (black), and for each of the monomers
(red for monomer I, green for monomer II). Snapshots were
taken every 10 ps. The RMSD was calculated after optimally su-
perimposing the atoms of the instantaneous conformation of
the dimer or each monomer on the X-ray structure.[9] The
RMSD compared to the X-ray structure remains below 2  for
most of the time during all individual 20 ns simulations, except
for occasional increases up to nearly 4 . Detailed analysis of
Table 1. Total energies of minimized monomers (M1, M2) and dimers (D) with and without the solvated Mg2+
ion.[a]
Structure Evac/Eh DEvac [kcalmol
1] Esolv/Eh DEsolv [kcalmol
1]
D 6118.13425 6118.74477
M1 3059.08454 3059.35134
M2 3059.08452 3059.35140
B3LYP/6-31** 21.8 26.4
B3LYP/6-31** (BSSE) 35.8 12.4
B3LYP/6-31** (CP) 68.8 20.6
B3LYP/6-311++G(2d,2p) 32.7 14.2
PBE1PBE/6-311++G(2d,2p) 26.9 19.3
2M 6118.16374 6118.70038
B3LYP/6-31** 18.2 27.8
B3LYP/6-311++G(2d,2p) 27.0 17.5
PBE1PBE/6-311++G(2d,2p) 21.4 22.9
D(Mg2+(H2O)4) 6624.30192 6624.55805
M1 3059.04533 3059.33935
M2 3059.04542 3059.33944
(Mg2+(H2O)4) 505.30574 505.69605
B3LYP/6-31** 568.2 115.0
B3LYP/6-31** (BSSE) 528.7 77.5
B3LYP/6-31** (CP) 282.5 7.4
B3LYP/6-311++G(2d,2p) 533.0 77.3
PBE1PBE/6-311++G(2d,2p) 551.9 95.6
[a] Total energies (for B3LYP/6-31G**) in Hartree (Eh), relative stabilization energies in kcalmol
1. The structures
in vacuum are optimized starting from the X-ray structure and give the vacuum energy Evac ; energies with im-
plicit solvent Esolv (PCM) are single-point calculations on the optimized vacuum structure. Stabilization energies
with B3LYP/6-31** (BSSE),[32] (CP),[33] B3LYP/6-311++G(2d,2p), and PBE1PBE/6-311++G(2d,2p) were calculated
on the optimized B3LYP/6-31G** structures.
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the trajectories reveals that the guanosine part of monomer I
opens its U-shaped structure during that time and then returns
to its original conformation.
In the minimum-energy structure, the Mg2+ ion is coordinat-
ed to two N7 atoms from each CDG monomer, which leads to
a wedge shape of the two central bases and induces a bend in
the stacking of the intercalated dimer. Furthermore, the X-ray
structure[4] shows that the Mg2+ ion, which is located between
the two monomers, is hydrated. This is partly because two of
the water molecules of the hydrated Mg2+ complex interact
with both oxygen atoms of the phosphate groups that are not
involved in H-bonding to the base N1 atoms. They also form
H-bonds to O6 atoms of the two central bases (see Figure 3).
In unbiased simulations of the metal-bound system the
Mg2+ ion spontaneously leaves the CDG dimer to form more
stable Mg2+(H2O)6 on a timescale of several hundred picosec-
onds. This is explained by comparing the partial charges on
the water oxygen atom (0.83e) and the CDG N7 atoms
(0.60e). Mulliken charge analysis of the ab initio calculations
(see above) on the metal-bound structure reveal that the par-
tial charges on the water oxygen and CDG nitrogen atoms are
0.65e and 0.60e, respectively. Thus, the parameterization of
the force field, especially for the nitrogen atoms of CDG are
meaningful and the propensity for Mg2+ to diffuse out of the
CDG dimer into solvent is qualitatively correct. Note that the
charges from ab initio calculations also include charge transfer
between Mg2+ and the water molecules in the first solvation
shell. Such effects can not be reliably captured with empirical
force fields. As discussed in the next paragraph, additional sim-
ulations with slightly increased charges on the CDG N7 atoms
(charge models II and III) lead to stabilization of the metal ion.
To sufficiently sample and estimate binding free energies for
the Mg2+-bound system two different approaches were ex-
plored. In one, the distance between the metal ion and the
two N7 atoms of the central guanosine base was biased with
an NOE restraint. In the other, the negative partial charge on
the N7 atoms was increased (models II and III in the Methods
Section) to provide a stronger interaction with the metal ion.
Using NOE restraints to maintain the Mg2+ ion at a position
close to that from the X-ray experiments reveals that the Mg2+
-bound CDG dimer remains close to its starting structure (see
Figure 4a), which is the X-ray structure (see Figure 1). Even
short openings of one of the monomers that were observed
for the metal-free system (Figure 2) do not occur, although this
would, in principle, be possible because the constraints only
affect the two N7 atoms of the two central guanosine bases
close to the Mg2+ ion and not the outer bases. To obtain more
physical insight, additional simulations were carried out with
charge models II and III. The increased negative charges on the
two N7 atoms were counterbalanced by increased positive
charges on neighboring atoms to maintain an integer overall
charge of the system (see Methods Section). It is found that
the metal ion remains coordinated to the CDG dimer and the
structure of the Mg2+-bound CDG dimer is stable for the entire
Figure 2. RMSD of the c-di-GMP dimer (black lines), as well as the first (red
lines) and second (green lines) monomers from individual 20 ns MD simula-
tions. Monomers I and II were fitted to the X-ray structure of monomers I
and II, respectively. Despite some large RMSD excursions (RMSD>2 ), the
dimer usually returns to a compact structure. Panels a) to e) are from five in-
dependent MD simulations.
Figure 3.Water molecules form hydrogen bonds (dotted lines) with the two
O6 atoms of the central bases of c-di-GMP and two oxygen atoms of the
phosphate groups.
Figure 4. RMSD for CDG (with respect to the X-ray structure) of Mg2+-bound
c-di-GMP dimer during the 10 ns MD simulations. CDG dimer (black), first
monomer (red), second monomer (green). a) RMSD of Mg2+-bound c-di-
GMP dimer with a NOE restraint ½Kmin; Kmax= [100, 200] kcalmol12.
b, c) RMSD for simulations with models II, III.
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10 ns simulation (Figure 4b and c). Figure 5a shows the tem-
poral variation of the N7Mg distances r(t) for a simulation
with NOE constraints ½Kmin; Kmax of [100, 200] kcalmol12, and
Figure 5b and c show the results of simulations with charge
models II and III. The distance r(t) typically fluctuates around
2–2.5 , which compares with a separation of 2.3  from the
X-ray structure.
In summary, the CDG dimer with and without Mg2+ appears
to be stable on the nanosecond timescale. The average
RMSD(t) is lower for the metal-bound dimer compared to the
system without metal as long as the metal ion remains coordi-
nated to the CDG dimer. After dissociation, the Mg2+ ion is co-
ordinated to six water molecules. Depending on the details of
the atomic charges, the charge disparity between the N7 nitro-
gen atoms of CDG and the oxygen atoms of the surrounding
solvent creates a driving force that leads to dissociation of the
metal ion and its subsequent solvation.
2.3. Dimerization Free Energy
To more quantitatively assess the stabilization of the metal-free
and metal-bound CDG dimer, the binding free energy DGbind is
calculated from the MD simulations by using MM-GBSA (see
Methods Section). Table 2 reports the different contributions to
the calculated dimerization free energy for the CDG dimer
from three different runs (each 10 ns). The general finding is
that the metal-free dimer is slightly favored over two separat-
ed monomers (by 5 kcalmol1). This is in line with the MD
simulations, which do not find dissociation of the dimer. How-
ever, the binding is weak, and within typical error bars of MM-
GBSA the dimer can be expected to be only marginally stable.
The error bars for the individual terms are typical for MM-
GBSA, as was already found in ligand-binding studies on HIV-1
protease.[36]
By using MM-GBSA it is possible to decompose DGbind into
favorable and unfavorable contributions. The loss of three
translational and three rotational degrees of freedom in the
process is entropically unfavorable. The total entropy change
(T DSh i ¼ Tð DStransh i þ DSroth i þ DSvibh iÞ is negative, because
T DSvibh i is too small to compensate the contribution from
T DStransh i. So the entropic contribution T DSh i is overall posi-
tive and thus destabilizing (see Table 2). It is also of interest to
compare the RMSD(t) traces in Figure 2a and c in view of the
computed DG values. Given the rather stable trajectory in Fig-
ure 2c, which shows almost no large-RMSD excursions, it is ex-
pected that this dimer is most strongly bound, whereas for the
trajectory in Figure 2b multiple attempted separations, in par-
ticular between 6 and 7 ns, are observed, which should desta-
bilize the system. This is indeed also reflected in the DG
values, which differ by 1 kcalmol1. A distinction between
run 1 and run 2 is less obvious because the RMSD(t) in Fig-
ure 2a is around 2  for 2 ns contrary to an increase of the
RMSD(t) in Figure 2b to more than 3  for about 1 ns.
For estimating the stabilization of the metal-bound CDG
dimer, the definition of the thermodynamic cycle to be consid-
ered is less obvious. Because in the X-ray structure the Mg2+
ion is coordinated to four water molecules and the CDG dimer,
the following scheme was chosen. First, the stability of
(CDG)2Mg
2+(H2O)4 with respect to separated (CDG)2+
Mg2+(H2O)4 was determined. In a next step, the stability of
(CDG)2 compared to 2CDG was calculated (see above). This is
not a unique decomposition, but given the observation that in
unbiased simulations the Mg2+ ion spontaneously leaves the
CDG dimer, such a decomposition scheme is useful.
In order to have a sufficient number of snapshots from
which to obtain meaningful statistics, trajectories with NOE
constraints [100,200] kcalmol12 on the N7Mg2+ separa-
tion were analyzed. Table 3 reports the different contributions
to the dimerization free energy of the metal-bound system.
The total hDGi for the first step [(CDG)2Mg2+(H2O)4!(CDG)2+
Mg2+(H2O)4] is 15.8 kcalmol
1, which suggests that Mg2+(H2O)4
prefers to dissociate from the CDG dimer. This is in line with
the observation that in unconstrained simulations of solvated
(CDG)2Mg
2+(H2O)4, the Mg
2+ ion prefers the aqueous environ-
ment (see above). On the other hand, the decomposition
energy of (CDG)2 into two separate monomers is 1.9 kcalmol
1
which is again indicative of a marginally stable CDG dimer and,
Figure 5. Distance r between Mg2+ and two N7 atoms in monomer I (g)
and monomer II (c). a) Analysis from the trajectory using NOE restraint
½Kmin; Kmax= [100, 200] kcalmol12 b, c) Analysis from trajectories with dif-
ferent charges redistribution of the guanosine base: b) model II ; c) model III.
Table 2. Dimerization free energies [kcalmol1] of c-di-GMP dimer from
three independent 10 ns MD simulations in explicit solvent at T=300 K.[a]
Energy contribution Run 1 Run 2 Run 3
DEvdWh i 30.06(4.15) 30.01(3.87) 30.76(3.37)
DEeleh i 78.88(9.25) 78.56(9.26) 76.94(9.09)
DGele;desolv
  67.27(7.58) 67.80(7.82) 65.96(7.46)
DGnp;desolv 3.62(0.25) 3.62(0.23) 3.69(0.18)
DG0bind
 þ DGdesolvh i 22.70(5.17) 22.30(5.33) 23.47(4.36)
T DStransh i 13.02 13.02 13.02
T DSroth i 10.61 10.62 10.62
T DStvibh i 6.09 5.89 5.59
DGbindh i 5.16 4.55 5.42
[a] The free energies were calculated using MM-GBSA as outlined in the
Methods Section.
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if error bars are included, in
agreement with the results from
Table 2. The difference between
DG calculated from the (CDG)2
and (CDG)2Mg
2+(H2O)4 trajecto-
ries is that the latter were con-
strained, which also influences
the conformational space avail-
able to the individual CDG mole-
cules and therefore affects the
estimated DG. This can also be
seen in comparing the RMSD(t)
traces in Figures 2 and 4.
Simulations with different
values of the NOE constraint
gave slightly different dimeriza-
tion free energies. Three trajec-
tories (with restraints [0,0] ,
[100,200], and [500,1000]) were
analyzed. The binding free ener-
gies of Mg2+(H2O)4 with (CDG)2 and the total binding energies
of Mg2+(H2O)4 and two CDG monomers are [17.0, 15.8,
14.6] kcalmol1, and [18.6, 17.7, 15.7] kcalmol1, respectively,
that is, the NOE restraint does not appreciably affect the total
binding free energy of the system. The binding free energy for
the simulation without restraints [0,0] was evaluated over a
3 ns portion of the [100,200] simulation for which the N7Mg
distance was between 2.0 and 2.9  which corresponds to dis-
tances for which the NOE constraint is not active (see Methods
Section). In addition, the total binding free energy of
(CDG)2Mg
2+(H2O)4 with respect to
Mg2+(H2O)4+CDG+CDG calculated from trajectories with in-
creased negative partial charges on the two N7 atoms
(model III, see Methods Section) is 10.7 kcalmol1 (see Table 4).
Thus, also with increased charges for which the Mg2+ ion re-
mains coordinated to (CDG)2 and the binding free energy is
5.7 kcalmol1, the (CDG)2 dimer is not stable.
3. Discussion and
Conclusions
Despite its central role as a
second messenger involved in
cell signaling, surprisingly little is
known about the structure, dy-
namics, and energetics of cyclic
diguanosine monophosphate at
the molecular and atomistic
level. Here, atomistic simulations
of metal-free and metal-bound
CDG were used to better charac-
terize the association state of
CDG in solution. Estimated bind-
ing free energies from MM-GBSA
including explicit solvation and
the nuclear dynamics suggest that the CDG dimer is only mar-
ginally stable with respect to its dissociated form (2CDG),
whereas the Mg2+ ion readily dissociates from (CDG)2 and pre-
fers water coordination. The fact that Mg2+ dissociates from
(CDG)2 in solution is related to the partial charges on the
atoms with which the metal ion interacts preferentially (N7 of
CDG and O of water). Electronic structure calculations show
that the charges and their relative magnitude used here are
meaningful. Simulations with slightly modified charges
(models II and III) show that Mg2+ indeed stabilizes in the form
known from X-ray crystallography. However, it is quite likely
that the interaction mode of Mg2+ with (CDG)2 in the crystal
and in solution differs and comparison with data from experi-
ments in solution will be very interesting.
Previous work with MM-GBSA has shown that, depending
on the system, typical error bars for free energies range be-
tween 3 and 6 kcalmol1.[29,25] Not surprisingly, calculations ex-
cluding entropic effects tend to overestimate experimentally
Table 3. Different contributions [kcalmol1] to the dimerization free energy of c-di-GMP with Mg2+ from simu-
lations at T=300 K with NOE restraint ½Kmin; Kmax= [100,200] kcalmol12.[a]
a) (CDG)2Mg
2+(H2O)4!Mg2+(H2O)4+ (CDG)2[b] b) (CDG)2!2CDG[b]
DEvdWh i 8.03(3.85) 28.14(3.06)
DEeleh i 555.58(16.74) 100.97(9.21)
DGele;desolv
 
550.49(15.26) 79.70(6.50)
DGnp;desolv 1.94(0.04) 3.53(0.12)
DG0bind
 þ DGdesolvh i 1.00(6.31) 10.39(5.64)
DHðaþbÞ
  9.39
T DStransh i 11.82 13.02
T DSroth i 8.09 10.63
T DSvibh i 5.09 11.38
DGbindða=bÞ
 
[c] 15.82 1.88
DGbindðaþbÞ
 
[c] 17.7
[a] The total simulation time is 10 ns. [b] a) The Mg2+-bound dimer dissociates into the hydrated Mg2+ and
metal-free dimer. b) The metal-free dimer dissociates into two separate monomers. [c] DGbindða=bÞ
 
is the bind-
ing free energy for step a) or b), respectively, whereas DGbindðaþbÞ
 
is the free energy difference for the overall
process (a and b).
Table 4. Different contributions to the dimerization free energy of c-di-GMP with Mg2+ from simulations at
T=300 K using charge model III and MM-GBSA (See Methods Section).[a]
a) (CDG)2Mg
2+(H2O)4!Mg2+(H2O)4+ (CDG)2[b] b) (CDG)2!2CDG[b]
DEvdWh i 14.42(4.79) 25.29(3.12)
DEeleh i 613.41(15.75) 109.03(9.43)
DGele;desolv
 
583.29(12.14) 80.12(6.65)
DGnp;desolv 1.95(0.04) 3.44(0.13)
DG0bind
 þ DGdesolvh i 17.65(5.90) 0.18(6.31)
DHðaþbÞ
  17.47
T DStransh i 11.82 13.02
T DSroth i 8.10 10.64
T DSvibh i 7.94 7.50
DGbindða=bÞ
 
[c] 5.67 16.34
DGbindðaþbÞ
 
[c] 10.67
[a] In this simulation the Mg2+ ion remains coordinated to the CDG dimer (see text). The total simulation time
is 10 ns. [b] a) The Mg2+-bound dimer dissociates into hydrated Mg2+ and metal-free dimer. b) The metal-free
dimer dissociates into two separate monomers. [c] DGbindða=bÞ
 
is the binding free energy for step a) or b), re-
spectively, and DGbindðaþbÞ
 
the free energy difference for the overall process (a and b).
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determined binding free energies. For Ras-Raf the calculated
binding free energy of 47.1(5.4) kcalmol1 compares with
9.6 kcalmol1 from experiment, whereas for Ras-RalGDS and
for insulin DG without entropic contributions is 50.0(5.6)
versus 8.4 and 38.7(5.8) versus 7.2 kcalmol1, respective-
ly.[29,25] Including entropic contributions brings calculations and
experiment into much better agreement. For Ras-Raf
DGMMGBSA  15:0ð6:3Þ kcalmol1, whereas for Ras-RalGDS
and insulin dimer they decrease to 19.5(5.9) and 11.9
(6.7) kcalmol1, respectively. For (CDG)2 excluding entropic ef-
fects, MM-GBSA yields DG0bind
 þ DGdesolvh i  22 kcalmol1
(see Table 2). As for the other systems mentioned above, it is
expected that this overestimates the real stabilization consider-
ably. However, it is interesting to note that the solvation ener-
gies DEsolv from most of the quantum chemical calculations are
in the range of 12 to 26 kcalmol1 and thus agree quite fa-
vorably with the MD results. Including entropic effects, ac-
counting for the errors in MM-GBSA and the fact that MM-
GBSA usually leads to overstabilization of a few kilocalories per
mole, DGMMGBSA  5 kcalmol1 (see Table 1) indicates that
(CDG)2 in solution is only marginally stable, if at all.
These observations have implications for the molecular
mechanisms involved in binding of CDG to its protein partners.
First, the results indicate that CDG in the cell is present in its
metal-free form. Second, the simulations in solution suggest
that the metal-free CDG dimer (CDG)2 is thermodynamically
stable by at most 5 kcalmol1 (see Table 2) relative to two
monomers. This is in agreement with experimental studies
which suggest that, depending on the concentration of CDG
present, dimers or higher oligomers form.[5] The present simu-
lations correspond to a concentration of about 80 mm, which
is at the upper range of concentrations found in vivo. Where
reported, typical concentrations in cocrystallization experi-
ments range from 0.2 to 5 mm.[11,37] Average physiological con-
centrations of CDG are in the submicromolar range.[38] Howev-
er, because in vitro experiments are usually carried out with
whole-cell extracts and disregard cell structure, local concen-
trations may be considerably higher.[5] It is therefore possible
and likely that the CDG concentration, and thus the equilibri-
um between its monomeric and dimeric form, varies considera-
bly under physiologically relevant conditions, which is also
consistent with the view that control of c-di-GMP concentra-
tions in bacteria is extremely complex and may also involve
concentration gradients.[39]
The experimental observation of a linear monomer[11,37,40, 41]
lead us to consider whether the linear monomer is energetical-
ly favored over the U-shaped structure found in (CDG)2. This
was quantitatively analyzed here by carrying out ab initio cal-
culations at the B3LYP/6-31G** level on the CDG monomer
conformations in different crystal structures. PilZ (PDB code:
2RDE[11]) and PleD (PDB code: 1W25[9]) bind a U-shaped mono-
mer whereas FimX, YkuI, and BlrP1 bind a stretched monomer
(PDB codes: 2W27,[41] 3V8,[11] 3GFX[37]). To compare these struc-
tures, the CDG monomers were all optimized to a local mini-
mum, and total energies in vacuo and with implicit solvent
(see above) were determined. In vacuo the linear structure
from YkuI (PDB code: 2W27) is lowest in energy followed by
the optimized U-shaped structure from PleD (2.2 kcalmol1
higher). Other conformations are destabilized by between 2.8
and 11.4 kcalmol1. Including solvation effects makes the U-
shaped structure from PleD lowest in energy, followed by the
linear structure from 2W27 (1.1 kcalmol1), and the remaining
local minima are destabilized by between 2.1 and
7.9 kcalmol1. Starting from a U-shaped structure from PleD,
the CDG monomer adopts a more elongated conformation
upon optimization (see Figure 6). Thus, the potential-energy
surface seems to be quite rugged, to support a larger number
of local minima, and CDG appears to be sufficiently flexible to
adapt to linear and U-shaped structures likewise with a rela-
tively small energy penalty. This is also required given the dif-
ferent protein environments it must adapt to. The electronic
structure calculations support the notion that CDG monomer
is flexible and able to either adopt quasilinear (extended) or
more U-shaped (compact) structures.
Recently, it was demonstrated that activated PleD specifically
localizes at the developing pole of Caulobacter crescentus cells.
Coupling of activation and subcellular sequestration could indi-
cate local concentration maxima.[8,42] The results presented
here suggest that what binds to PleD in such high CDG con-
centration regions is actually (CDG)2. Finally, experimentally, it
is found that both, CDG monomers (PleD,[9] BlrP1,[37] YkuI,[40]
FimX,[41] PilZ[11]) and dimers (PleD,[9] WspR,[10] PP4397[12]) bind to
proteins. Therefore, the simultaneous presence of CDG and
(CDG)2 may be advantageous or even required in a concrete
biological context. Furthermore, the weak preference of (CDG)2
over 2CDG found in the present case for the high-concentra-
tion limit would provide the cell with a flexible mechanism to
make both forms of the messenger available. Consequently, at
any given instance, there will be a more or less significant
amount of CDG or (CDG)2, which is capable of binding as a
monomer or as a dimer, respectively, depending on the re-
quirements of the protein. Consequently, the proposal of pro-
tein-induced sequestration of (CDG)2 in PleD, although still
speculative, may be a very appropriate picture.[43]
Figure 6. Structures of the CDG monomer from Pled (PDB code 1W25). Ball-
and-stick structure: crystal structure of the U-shaped CDG monomer from
the intercalated dimer. Line structure: optimization structure of the U-
shaped CDG monomer from the intercalated dimer.
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4 Bacterial Second Messenger c-di-GMP
4.2 Dynamics of Analogue endo-S-c-di-GMP in Solution
In the previous section, the structure and association affinity of c-di-GMP in solution
were investigated. Through interaction with different receptors, c-di-GMP negatively
modulates cell motility and traits associated with bacterial virulence and stimulates
several biofilm-associated functions. High concentrations of c-di-GMP promote sessile
(biofilm formation) growth while low concentrations of c-di-GMP promote motile growth.
The aggregation of c-di-GMP into higher aggregates will reduce its concentration in the
cell. It will be of interest to determine which moieties of c-di-GMP promote aggregate
formation.
In the next section, to further characterize c-di-GMP, investigations on a c-di-GMP
analogue called endo-S-CDG are presented. endo-S-CDG is obtained by modification of
one of the phosphate groups in c-di-GMP with a sulfur in the phosphodiester linkage. To
compare with c-di-GMP, MD simulations with endo-S-CDG in solution were carried out.
Moreover, endo-S-CDG binding to PleD protein was studied to reveal the role played by
the phosphodiester linkage in c-di-GMP dimerization and binding to processing proteins.
A paper is in preparation.
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Abstract
Cyclic diguanosine-monophosphate (c-di-GMP, CDG) is a bacterial signaling molecule that triggers a
switch from motile to sessile bacterial lifestyles1,2. Analogues of c-di-GMP, which can selectively modulate
the activities of c-di-GMP processing proteins, will be useful chemical tools for studying and altering
bacterial behavior. Recent studies3,4 revealed that c-di-GMP is a monomeric state at low micromolar
concentration (1 µ M) in the absence of metal ions and dimerization may occurs only on the proteins
(i.e., diguanylate cyclase, PilZ ). Higher oligomer formation occurs only in the presence of monovalent
(particularly K +) metal ions. Another report5 showed that a conservative modification of one of the
phosphate groups in c-di-GMP with a bridging sulfur in the phosphodiester linkage affords an analogue
called endo-S-c-di-GMP does not readily form higher aggregates. Local c-di-GMP pools with higher
concentrations have been discussed1, but so far remain hypothetical. In our work, we presented Molecular
Dynamic Simulation on endo-S-c-di-GMP in aqueous solution with a concentration of 80 mMol. The
result shows the dimerization free energy of endo-S-c-di-GMP is −0.43 kcal/mol compared to −5 kcal/mol
for the c-di-GMP dimer, which indicates that the former is less favoured in dimeric form. This finding
suggests that the phosphate in c-di-GMP is important in aggregate formation and may also in the binding
of c-di-GMP to proteins.
1
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I. INTRODUCTION
Cyclic diguanosine-monophosphate (c-di-GMP) is a ubiquitous second messenger that regu-
lates cell surface-associated traits in bacteria. It has attracted considerable attention from different
fields since it was discovered 20 years ago.1–14 Cyclic di-GMP is a monocyclic RNA dinucleotide
and has a conformation in which the 12-membered circular sugar-phosphate backbone provides
a rigid framework to hold the two adenines 6.8 A˚ apart in parallel planes.7 It is produced
from 2 molecules of GTP by the activity of diguanylate cyclases (DGCs) and is degraded by
specific phosphodiesterase (PDE) into 5’-phosphoguanylyl-(3’-5’)-guanosine (pGpG); pGpG is
subsequently split into two GMP molecules. Through the interaction with different receptors,
such as PilZ15 - containing proteins, c-di-GMP negatively modulates cell motility and traits
associated with bacterial virulence and stimulates several biofilm-associated functions. High
concentrations of c-di-GMP promote sessile (biofilm formation) growth while low concentrations
of c-di-GMP promote motile growth.
Binding of c-di-GMP to a secondary site (I site) that is present in most DGCs results in feedback
product inhibition of these enzymes and contributes to a physiological upper limit to cellular
accumulation of c-di-GMP.16 Indeed, two c-di-GMP molecules can form a mutually intercalated
dimer structure stabilised by multiple forces including hydrogen bonds from the base of one
molecule to the sugar phosphate backbone of the other, and guanine guanine base-pairing
interactions.3,6,7
Chemical modifications of c-di-GMP have been recently studied because structural changes may
affect the aggregation properties of the molecule and also modulate its affinity and interaction
with the proteins to which it binds. One conservative chemical change to c-di-GMP is to modify
one of the oxygen atoms in the phosphodiester linkage by a bridging sulfur which yields the
endo-S-CDG analogue (see Figure 1). Experimentally, endo-S-CDG was studied by using NMR
and CD spectroscopies which found a reduced aggregation propensity compared to c-di-GMP.5
Furthermore endo-S-CDG binds to RocR, a PDE that binds monomeric c-di-GMP, and inhibits
hydrolysis while it did not bind to WspR (to which dimeric c-di-GMP binds) or the PilZ domain
protein Alg44.17 This demonstrates that selective binding to different classes of c-di-GMP binding
proteins is possible by chemically altering c-di-GMP.
2
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FIG. 1: (a)Structure of c-di-GMP monomer (X= O) and endo-S-CDG by substituting the bridging Oxygen
atom by sulfur. Atoms C5, and N7 are labelled as well. (b) Structure of intercalated c-di-GMP dimer.
Currently, there is no available crystal structure in the PDB that contains endo-S-c-di-GMP
cocrystallized in a host protein. As is shown in Table I, both closed and open c-di-GMP can be
bound to the active site of a range of proteins, including Wspr18,19, PleD16,20, the PilZ domain15,21
Ykui22, Fimx,23 or LapD24. DGC and PilZ-domain-containing proteins bind closed c-di-GMP
whereas EAL-domain-containing proteins bind open c-di-GMP.
In the present work we use computational techniques to study the aggregation behaviour of endo-
3
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TABLE I: Proteins, Domains containing c-di-GMP in the protein data bank
Domain Protein PDB code Unit Num. and form CDG
EAL Ykui 2W2725 Dimeric 2 open CDG
EAL Fimx 3HV826 Monomeric 1 open CDG
BLUF-EAL BlrP1 3GG127 Dimeric 2 open CDG
BLUF-EAL BlrP1 3GG027 Dimeric 2 open CDG
BLUF-EAL BlrP1 3GFZ27 Dimeric 2 open CDG
BLUF-EAL BlrP1 3GFY27 Dimeric 2 open CDG
BLUF-EAL BlrP1 3GFX27 Dimeric 2 open CDG
EAL LapD 3PJU28 Dimeric 2 open CDG
EAL LapD 3PJT28 Dimeric 2 open CDG
EAL-GGDEF Q3SJE6 3N3T29 Dimeric 2 open CDG
REC-GGDEF Wspr 3I5A30 Tetrameric 1 dimer
REC-GGDEF Wspr 3BRE31 Dimeric 2 dimer
REC-REC-GGDEF PleD 2V0N32 Dimeric 2 dimer
REC-REC-GGDEF PleD 1W2533 Dimeric 2 dimer, 1 closed CDG
REC-REC-GGDEF PleD 2WB4 Dimeric 2 dimer, 1 closed CDG
GGDEF XCC4471 3QYY34 Dimeric 2 closed CDG
bzzp-1 GGDEF Wspr/GCn4 3I5C35 Dimeric 2 closed CDG
GGDEF MqR89a 3IGN Monomeric 1 closed CDG
GGDEF-GAF2 Peld156-455 4DN036 Monomeric 1 closed CDG
PilZ pa4608 2L7437 Monomeric 1 dimer
PilZ pp4397 3KYF38 Monomeric 1 dimer
PilZ PlzD(Vca0042) 2RDE39 Dimeric 2 closed CDG
PilZ XAC1133 3KYG40 Dimeric 2 dimer
4
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S-CDG in gas phase and in solution. For this, electronic structure calculations and molecular
dynamics simulations with explicit solvation are carried out. From the latter the binding free
energy of the dimer in solution can be estimated which provides information about the aggregation
state in solution. Finally, we also consider the dynamics of endo-S-CDG and c-di-GMP in their
monomeric and dimeric forms in the typical c-di-GMP-binding protein PleD.
II. COMPUTATIONAL METHODS
A. Electronic Structure Calculations
Density functional theory (DFT) calculations were carried out with Gaussian 0341 at the
B3LYP/6-31G(d,p) level.42,43 The starting structure for endo-S-CDG was obtained by substituting
one of the oxygen atoms in the phosphodiester linkage in c-di-GMP ([Brookhaven Protein Data
Bank (PDB)44]. For the Mg2+−bound c-di-GMP dimer coordinates from the Cambridge Struc-
tural Database were used.6,45 The overall charge is −4 for the mutually intercalated endo-S-CDG
dimer and −2 for the Mg2+−bound endo-S-CDG dimer.
B. Molecular Dynamics Simulations
Molecular dynamics (MD) simulations for the dinucleotides were carried out with the
CHARMM program46 using the CHARMM22 force field47 with periodic boundary conditions
(PBC). Force field parameters for c-di-GMP were those determined and used previously.3,48,49
Force field parameters for sulfur were fitted to reproduce the energy surface scans of the respective
coordinates obtained from DFT calculations. Bonded force field parameters (see below) involving
the sulfur atom were fitted to reproduce DFT energy scans of the respective internal coordinates
which included the P-S and S-C distances, the CCS, CSP, HCS and SPO angles. The coordinates
were scanned on a grid of 0.05 A˚ , 1◦ around the minimum structure for 30 points. The fitting
was performed using Chnolls50, the CHARMM interface for Inolls.51 The overall correlation
coefficient for the fit is R = 0.90 with a mean square deviation for the energies of 2.89 kcal/mol.
This data is shown in figure 1 of the supplementary information. The Mulliken charges from DFT
5
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FIG. 2: Optimized geometry of (a) endo-S-CDG monomer, (b) CDG monomer, (c) endo-S-CDG dimer,
(d) CDG dimer from DFT calculation at B3LYP/6-31G(d,p) level. Four structures are shown in (a) and (b)
respectively, corresponding to constraint and fully optimized structures of U-shaped endo-S-CDG, CDG
(PDB code: 1w25) and open-shaped endo-S-CDG, CDG (PDB code: 2W2722). For U-Shaped endo-S-
CDG, CDG, the distance of C5 in the guanine of CDG is 6.83 A˚, while for open-shape endo-S-CDG, CDG,
the distance of C5 is 13.5 A˚. Fully optimized endo-S-CDG, CDG, the distance of C5 is between 6.8 –13.5
A˚.
minimizations were used for the MD simulations.
The structures of the metal-free and Mg2+−bound endo-S-CDG dimer were optimized with
5000 steps of steepest descent minimization. Then the complexes were individually solvated in
a pre-equilibrated water box of dimension 37.3× 34.1× 34.1 A˚3. The solvent was optimized
and equilibrated at 300 K for 30 ps in the presence of the fixed solute. Finally, the structures
of the solutes were relaxed with 2000 steps of steepest descent minimization and then gradually
6
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heated to 300 K for 200 ps followed by 1 ns of equilibration. All MD simulations were carried
out by using SHAKE52 to constrain the bonds involving hydrogen atoms. For the metal-bound
and metal-free endo-S-CDG dimer 3 independent trajectories (60 ns in total) and 12 independent
trajectories (240 ns in total) were run, respectively.
For simulations of the Mg2+−bound endo-S-CDG dimer the metal ion has a finite probability to
escape to the solvent because it only interacts via electrostatic interactions with its environment.
Therefore, the MD simulations used a NOE constraint to maintain the magnesium ion closer to
the N7 nitrogen atoms of the central guanosine. The force constants [Kmin,Kmax] were [100,200]
kcal/(mol A˚2).
For endo-S-CDG and CDG dimer bound to PleD, MD simulations were carried out with either
CHARMM or NAMD53 using the CHARMM22 force field. The starting structures are the A
chain from the X-ray dimer (PDB code: 1W2520) and the GGDEF domains of X-ray dimer
(PDB code: 2WB4), respectively. Thus for both proteins the simulation systems consist of
the protein monomer, an intercalated endo-S-CDG/CDG dimer in the inhibition (I-)site, and a
endo-S-CDG/CDG monomer in the active (A-) site. The systems have an overall charge of −9e
and −14e for inactive PleD (1W25) and the active PleD (2WB4), respectively. First, 500 steps
of steepest descent minimization were run. followed by heating and equilibration dynamic in a
pre-equilibrated waterbox of TIP3P54 water molecules extending 10 A˚ in all dimensions around
the solute which leads to simulation systems consisting of ≈ 100000 atoms. Afterwards, the
systems were neutralized with an adequate number of Na+ counter-ions and PME55 was employed
for the calculation of the electrostatics beyond the cutoff of 12 A˚ of the explicit calculation. All
systems were heated for 30 ps to 300 K and equilibrated for 200 ps with the solute fixed and then
totally relaxed for another 1 ns before production simulations started. The simulation length is 20
ns for each trajectory.
C. Dimerization Free Energy
The binding free energy ∆G consists of an enthalpic (∆E) and an entropic contribution (∆S),
which can be calculated according to a thermodynamic cycle.56,57 Here, the molecular mechan-
7
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FIG. 3: Structure of inactive (panel a, PDB code: 1W25) and activated (panel b, PDB code: 2WB4) PleD.
The part marked by cyan color is the system studied here. Green: DGC; red: D1 domain; yellow: D2
domain.
ics with generalized Born surface area (MM-GBSA) approach58 is used which decomposes the
binding free energy, ∆Gbind into a sum of the gas phase contribution, the desolvation energy of the
system upon binding, ∆Gdesolv, and an entropic contribution, −T ∆S:
∆Gbind = 〈∆G0bind〉+ 〈∆Gdesolv〉−T 〈∆S〉 (1)
The brackets indicate averages of the individual terms along an equilibrium MD simulation59.
The gas phase contribution, 〈∆G0bind〉, consists of the difference in van der Waals and electrostatic
energies between the dimer (D) and the individual monomers (M) whereas the desolvation term
consists of a nonpolar contribution which is assumed to be proportional to the solvent-accessible
surface area (SASA) and an electrostatic contribution calculated with the GB-MV2 model.60,61 A
value of 0.0072 kcal/(mol A˚2 ) was used to relate the buried SASA to the non-polar desolvation
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free energy59,62,63.
∆Gbind = 〈∆G0bind〉+ 〈∆Gdesolv〉−T 〈∆S〉
= 〈∆Eintra〉+ 〈∆Evdw〉+ 〈∆Eelec〉+ 〈∆Gele,desolv〉+ 〈∆Gnp,desolv〉−T 〈∆S〉 (2)
The energies calculated for snapshots taken every 10 ps using the ”same trajectory method”
(STM)59 were averaged over 20 ns. In the STM, the energy terms relative to the isolated monomers
are calculated using coordinates taken from the simulation of the dimer. The entropy term is parti-
tioned into translational, rotational and vibrational terms following standard equations of statistical
mechanics.64 The translational contribution only depends on the mass of the system and the ro-
tational part is related to the moments of inertia. The vibrational part can be calculated from the
normal modes (NM) νi:
−T ∆Si = hνi
e
hνi
kBT −1
− kBT ln(1− e−
hνi
kBT ) (3)
where kB is the Boltzmann constant h is the Planck constant and T = 300 K. The VIBRAN module
of the CHARMM program was used to calculate and diagonalize the force constant matrix to
determine the normal mode vectors and frequencies. Normal modes were calculated both for the
fully minimized structures of the dimer and the monomers in vacuo with a distance dependent
dielectric (ε = 4), and a cutoff of 12 A˚ for non-bonded interactions was applied. The snapshots
were minimized using the adopted basis Newton Raphson (ABNR) method until a gradient of
10−7 was reached. All reported values are averaged over 1000 frames, equally distributed over the
20 ns trajectories.
III. RESULTS AND DISCUSSION
A. Electronic Structure Calculations
DFT calculations for the minimum energy conformation of the endo-S-CDG monomer were
started from the closed and the open conformation. The two states are characterized by a C5–C5
distance of 6.8 A˚ and 13.5 A˚, respectively, see Figure 1. For the endo-S-CDG dimers the
optimized structures of the metal-free and hydrated Mg2+ (Mg2+(H2O)4) were determined. For
all systems the structures were fully optimized starting from the X-ray coordinates. Additionally,
constrained optimizations, whereby the C5–C5 distance was fixed at 6.8 A˚ (U-shaped, ”closed”)
and 13.5 A˚ (fully extended, ”open”), respectively, were carried out. These distances correspond to
9
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the distance of the monomer in the X-ray structure of the c-di-GMP dimer6 and that in the crystal
together with Protein PleD20. For analyzing the structures of monomeric and dimeric endo-S-
CDG the structures of c-di-GMP in the crystal structures of 1W2520, 2WB444, 2W2722 were
used whereas for the Mg2+–bound dimer the reference was the X-ray structure of Mg2+–bound
c-di-GMP.6
The RMSD of the closed endo-S-CDG monomer with and without C5 constraints, and the
open endo-S-CDG monomer with and without C5 constraint are 0.62, 2.03, 1.01, and 1.11 A˚,
respectively. For the constrained systems, which are less relevant, similar RMSDs were found
for conventional c-di-GMP (CDG) - they are 0.47 and 1.14, compared to 0.62 and 1.01 A˚ for
endo-S-CDG - whereas the unconstrained optimizations remain closer to the X-ray structure in
the case of conventional CDG (they are 0.80 and 0.60, compared to 2.03 and 1.11 A˚).3 Hence,
replacing an oxygen atom by a sulfur atom leads to observable differences in the minimum energy
structure, in particular for the monomer. For the dimeric structures, the RMSD to the X-ray
structure for CDG and endo-S-CDG are similar. For the endo-S-CDG dimers with and without
hydrated Mg2+ bound to it the RMSDs are 0.32 and 3.21 A˚, respectively.
The energies of endo-S-CDG dimer and endo-S-CDG dimer with Mg2+ from DFT calculations
are reported in Table II. The destabilization energy of the endo-S-CDG dimer in the gas phase
relative to two separated monomers is ∆E1 = Edimer−(EdimerM1 +EdimerM2 ) = 27.6 kcal/mol. Including
solvation effects this leads to a stabilization by −19.4 kcal/mol. As a comparison, the CDG
dimer has been found to be stabilized by −27.8 kcal/mol relative to the separated monomers.
This suggests that both, endo-S-CDG and CDG are stable in their dimeric forms although CDG
is more strongly bound. For the Mg2+−bound endo-S-CDG dimer the binding energies ∆E are
−555.8 and −111.9 kcal/mol in gas phase and solution, respectively.
Optimized structures, with and without constraint of the C5 distance for both, the endo-S-CDG
and the CDG monomer, are shown in Figures 4a,b. The total electronic energies of both monomers
in solution are reported in Figure4 and Table II relative to the energy of the constrained optimiza-
tion of the closed monomers. Starting from the closed conformer, the minimum energy structure
for endo-S-CDG is stabilized by −3.50 kcal/mol whereas for CDG it is almost isoenergetic which
suggests that the potential energy surface is very flat. Starting from the constrained optimization
10
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TABLE II: Total energies of minimized endo-S-CDG monomers, M1,M2 and dimers (D) with and without
the solvated Mg2+ ion. Total energies in Hartrees (Eh), relative stabilization energies in kcal/mol. Structures
in vacuum are optimized starting from the X-ray structure and give the vacuum energy Evac; energies with
implicit solvent Esolv (PCM) are single-point calculations on the optimized vacuum structure.
Structure Evac/Eh ∆Evac/(kcal/mol) Esolv/Eh ∆Esolv/(kcal/mol)
D –6764.05667003 –6764.66080314
M1 –3382.04943669 –3382.31214372
M2 –3382.03477879 –3382.30356901
17.3 –28.3
2×M –6764.10064174 –6764.62985988
27.6 –19.4
2×M-close –6764.09456578 23.8 -6764.62013426 –25.5
D(Mg2+(H2O)4) –7270.18691562 –7270.44294429
M1 –3381.99433357 –3382.28445380
M2 –3381.99445385 –3382.28476163
(Mg2+(H2O)4) –505.312501382 –505.695405589
–555.8 –111.9
of the extended structures, the two fully optimized structures lead to a slight contraction with
concomitant energy reductions by 0.2 and 0.4 kcal/mol. Again, the PES is very flat. Overall, both
extended structures are energetically favoured over the U-shaped structure: for endo-S-CDG the
stabilization is 1.0 kcal/mol whereas for CDG it is 2.5 kcal/mol. The small energy differences
suggest that in solution both systems exist in a conformational equilibrium consisting of extended
and partially closed structures. However, for endo-S-CDG the energy differences between the two
states is somewhat larger (3.5 kcal/mol) than for CDG (2.5 kcal/mol). Thus, it is expected that the
CDG-dimer is more stable than the endo-S-CDG-dimer.
11
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FIG. 4: The energy of CDG and endo-S-CDG in solution from electronic structure calculation. R is the
distance of C5 in the guanine of CDG. The left panel shows the results of close CDG structures–partially
optimized CDG (constraint the C5 distance at 6.8A˚ ) and fully optimized (R = 8.3 A˚ for CDG and R = 11.1
A˚ for endo-S-CDG); the right panel is for open CDG structures –constraint the distance of C5 at 13.5 A˚ and
without constraint just fully optimized (R = 12.8 A˚ and 13.5 A˚).
12
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B. Dimer Dynamics in Solution
In order to characterize the dynamics of the endo-S-CDG dimer, atomistic simulations in full
solvation were carried out. Figure 5a shows the root mean square deviation (RMSD) from the X-
ray structure, calculated for the entire endo-S-CDG dimer. Snapshots are taken every 10 ps. The
RMSD was calculated after optimally superimposing the atoms of the instantaneous conformation
of the dimer or each monomer onto the X-ray structure (see above). The RMSD fluctuates between
2 and 3 A˚ with eventual excursions up to 4 A˚. This is somewhat larger than for the CDG dimer for
which we previously found typical RMSDs of around 1 A˚. The distance between the C5-atoms of
the guanine bases, which can be used to distinguish between an open and a closed monomer, is
around 7 A˚ for monomer I (see Figure 5b), with infrequent elongations up to 9 A˚. This suggests that
monomer I is still in its closed conformation. The distance between the C5 atoms of the guanine
bases on monomer II (Figure 5c) oscillates considerably since monomer II fluctuates between
closed and open conformations during the entire simulation. Compared to this, the chemically
unmodified CDG dimer shows less structural variability.3
Representative snapshots of endo-S-CDG dimer structures along the 20 ns MD simulation are
shown in Figure 5 of the supplementary information. In the simulations we find all possible
combinations of monomeric structures, including closed-closed, open-closed and open-open, see
Figure 5.
It is also of interest to consider the interaction energies of specific parts of endo-S-CDG within
the dimer. Figure 6(A) reports the total interaction energy contributed by individual energy
contributions: the inner guanine base of monomer II and monomer I; the outer, flexible guanine
base of monomer II and monomer I; the phosphodiester linkage of monomer II and monomer I.
The interaction energies of two monomers along the trajectory is in the range of 25 to 75 kcal/mol
whereas the interaction energies of monomer I and the inner and outer guanine of monomer II
are between –50 and –25 kcal/mol and between –20 and –10 kcal/mol. The interaction between
monomer I and the phosphodiester linkage of monomer II is strongly destabilizing and fluctuates
around 100 kcal/mol. Hence, we find overall enthalpic destabilization based on pure interaction
energies and stabilization of the dimer is entirely solvent-driven.
13
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FIG. 5: (a) RMSD of endo-s-CDG dimer from 20 ns MD simulations. Monomers I and II were fitted to the
X-ray structure of monomers I and II in 1W25, respectively. (b) The distance of C5-C5 of the guanine in
monomer I. Along the 20 ns simulation, the distance is around 7A˚, which shows that this monomer is still
in its closed state. (c) The distance of C5-C5 of the guanine in monomer II. The distance fluctuates since
monomer II oscillates between open and closed structures. (d) Enthalpic part ∆H of the dimerization free
energy for endo-S-CDG dimer along the 20 ns trajectory. When the distance is large in (c), the dimerization
energy is small.
C. Dimerization Free Energy
A more quantitative measure for the stability of endo-S-CDG than interaction energies
(either from electronic structure calculations or force field computations) is provided by the
dimerization free energy ∆Gbind as calculated from the MD simulations. This is done according
to MM-GBSA (see Methods section). Figure 5d already shows that the enthalpic part of the total
energy (including gas phase contribution and solvation part to the enthalpic ) is closely related
14
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FIG. 6: (A) The interaction energy along a 20 ns trajectory for endo-S-CDG. Black: total interaction energy
between endo-S-CDG monomer I and monomer II. Green: interaction energy between monomer I and
inner guanine base of monomer II. Yellow: interaction energy between monomer I and outer guanine base
(swing and turn the conformer to open shape) of monomer II. Pink: interaction energy between monomer I
and the phosphodiester linkage motif of monomer II. The inner guanine base, outer guanine base, and the
phosphodiester linkage motif is marked by green, yellow, pink respectively. (B) The snapshots of endo-
S-CDG dimer structures from the 13 individual 20ns simulation. (PDB code:1W25): (a) The intercalated
endo-S-CDG dimer; (b) One endo-S-CDG monomer stay as close shape, while another one turns to oepn
shape; (c) Two endo-S-CDG monomers are in open shape with two guanine base Π interaction.
to the conformations of the two endo-S-CDG monomers. Whenever the two monomers are in a
closed form the two monomers lock in an enthalpically favoured state whereas opening of one
monomer leads to destabilization by several 10 kcal/mol. The overall enthalpic stabilization
excluding entropic contributions is −18.8 kcal/mol, about 4 kcal/mol smaller than that for
15
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TABLE III: Contributions from the Side-Chains and the Backbone Atoms in both endo-S-CDG Monomers
to total Dimerization Free Energies (in kcal/mol) at T = 300 K. Free energies were calculated using MM-
GBSA outlined in the Methods Section.
Monomer I Monomer II
linkage bases M1 linkage bases M2 D-(M1+M2)
〈∆Evdw〉 -2.48 -10.29 -12.77 -2.15 -10.62 -12.77 -25.54(3.57)
〈∆Eele〉 47.38 -8.93 38.44 42.87 -4.43 38.44 76.89(10.17)
〈∆Gele,desolv〉 -47.55 14.07 -33.48 -46.88 13.47 -33.41 -66.89(8.25)
〈∆Gnp,desolv〉 -0.31 -1.36 -1.66 -0.17 -1.43 -1.59 -3.26(0.25)
〈∆G0bind〉+ 〈∆Gdesolv〉 -2.96 -6.51 -9.47 -6.32 -3.01 -9.33 -18.80(4.89)
〈−T ∆Stran〉 17.58
〈−T ∆Srot〉 10.69
〈−T ∆Svib〉 -6.89
〈−T ∆Stot〉 16.98
〈∆Gbind〉 -1.82
c-di-GMP.3 Table III reports the different contributions to the calculated dimerization free
energies for the endo-S-CDG dimer from a total of 0.25 µs simulations whereas analyses of
selected individual runs are presented in Table 1 of the SI. Including translational, rotational and
vibrational contributions to ∆S leads to ∆Gbind ≈ 0 and suggests that the metal-free endo-S-CDG
dimer is only marginally stable in solution. This compares with a binding free energy of ≈ −5
kcal/mol for the c-di-GMP dimer which has also been found to exist in dimeric form from NMR
experiments.3,4 Hence, the present simulations find that chemical modification at the phosphodi-
ester linkage destabilizes the endo-S-CDG and yields predominantly monomeric forms in solution.
The dimerization free energy for Mg2+−bound endo-S-CDG was also determined molecular dy-
namics simulations in explicit solvent. As mentioned in the methods section, the position of the
magnesium ion was constrained with an NOE constraint. Following an earlier study on c-di-GMP,
the thermodynamic cycle considered for MM-GBSA considered the dissociation of the solvated
Mg2+(H2O)4 from the solvated endo-S-CDG dimer.3 This leads to an enthalpic stabilization of the
magnesium-bound endo-S-CDG dimer by ∆H =−3.24 kcal/mol, compared to −9.39 kcal/mol for
16
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the CDG dimer. Details are provided in Table 2 in the SI. Including entropic contributions sim-
ilar to the Mg2+−free dimer above leads to an overall destabilization which was, however, not
determined explicitly here.
D. endo-S-CDG and CDG bound to inactive and active PleD
Physiologically it is of considerable interest to characterize the dynamics of endo-S-CDG
and c-di-GMP bound to proteins with which they interact. To provide more insight on this, MD
simulations for both molecules in the inactive (1W25) and activated (2WB4) structure of PleD
have been carried out. In both structures a mutually intercalated CDG dimer is bound in the
allosteric inhibition site (I-site) while a CDG monomer is present in the active site (A-site). The
structures used in these simulations are reported in Figure 3.
Figure 7 shows that both, endo-S-CDG and CDG dimers are stable in the I-site. The fluctuations
are larger in the inactive form (panels (a) and (b)) compared to the active form. Both monomers
show similar fluctuations which suggests that endo-S-CDG should also be stable in the inactive
and activated PleD. This is different for the dimers in solution where one of the monomers
can occasionally make a transition to an open form, specifically for endo-S-CDG. This is not
observed for any of the dimers bound to the protein. Binding monomeric endo-S-CDG and CDG
into 1W25 and 2WB4 leads to a slightly different picture. While CDG fluctuates appreciably in
the active site of inactive PleD, endo-S-CDG appears to better stabilize in this site, as is shown
in Figure 2 of the SI. The C5-C5 distance (see Figure 8), indicative of a “open” or a “closed”
monomer suggests that CDG in inactive PleD is in an equilibrium between the two conformations
(on the 10 ns time scale) whereas in the active form of the protein CDG is rather in an “open”
conformation. Conversely, endo-S-CDG is predominantly in a “closed” form in inactive PleD
whereas it also prefers an open conformation in activated PleD. It is worthwhile to note that all
four systems have RMSD around or below 2 A˚ during the 20 ns dynamics and hence the proteins
are overall stable (see Figure 3 in the SI). Hence, the activated form of the protein seems to favour
open endo-S-CDG/CDG which is less likely to dimerize whereas inactive PleD shifts this to more
closed forms reminiscent of a dimer structure.
17
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FIG. 7: RMSD of heavy atoms of CDG and endo-S-CDG which is bound to the inactive PleD (PDB
code:1W25) and active PleD (PDB code:2WB4). (a) CDG in inactive PleD (PDB code:1W25); (b) endo-
S-CDG in inactive PleD (PDB code:1W25); (c) CDG in active PleD (PDB code:2WB4); (d) endo-S-CDG
in active PleD (PDB code:2WB4). Black: CDG/endo-S-CDG dimer; Red: CDG/endo-S-CDG monomer1;
Green: CDG/endo-S-CDG monomer2.
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IV. CONCLUSIONS
The present work establishes that chemically modified CDG - endo-S-CDG - is less proba-
ble to form dimers in solution than CDG for which marginal stabilization has been found from
computations and experiment.3,4 Including entropic contributions in estimating the dimerization
free energy of endo-S-CDG, 250 ns of atomistic simulations give a slight stabilization of ≈ −2
kcal/mol. The metal-bound dimer is slightly more stable but comparison with Mg2+−bound
(CDG)2 suggests that the endo-S-CDG dimer is also only marginally stable in the presence of
magnesium. Both messengers are found to favourably interact with the active and inactive form
of PleD, a CDG-binding protein. In the inhibition site, both dimers are stable and in a predomi-
nantly “closed” form whereas in the active site the behaviour of endo-S-CDG and CDG differ to
some extent. It is interesting to note that the activated protein appears to favour “open” forms of
the monomeric messenger whereas the inactive protein supports both, “open” and “closed” forms.
These findings may provide essential insights into better characterizing the dynamics and function
of natural and chemically modified CDG.
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Table 1: Dimerization Free Energies (in kcal/mol) of endo-S-cdg dimer from three independent 20 ns MD simulations in explicit solvent
at T = 300 K. Free energies were calculated using MM-GBSA outlined in the Methods Section
〈∆Evdw〉 〈∆Eele〉 〈∆Gele,desolv〉 〈∆Gnp,desolv〉 〈∆E0bind〉+ 〈∆Gdesolv〉 〈−T ∆Stran〉 〈−T ∆Srot〉 〈−T ∆Svib〉 −T 〈∆S〉 〈∆Gbind〉
Run1 -27.36 77.94 -64.43 -3.37 -17.23 13.18 10.71 -7.09 16.80 -0.43
Run2 -28.66 77.20 -65.21 -3.46 -20.13 13.18 10.57 -7.61 16.29 -3.84
Run3 -25.23 70.37 -62.61 -3.31 -20.78 13.18 10.57 -6.89 16.86 -3.92
Run4 -26.39 72.91 -62.57 -3.38 -19.44 13.18 10.61 -6.90 16.89 -2.55
Run5 -25.24 76.39 -62.93 -3.26 -15.05 13.17 10.69 -6.90 16.96 1.91
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Table 2: The different contributions to the dimerization free energy of endo-S-cdg with Mg2+ from simulations at T = 300 K with NOE
restraint [Kmin, Kmax] = [100, 200] kcal/(mol Å2) The total simulation time is 10 ns. (a) Mg2+− bound dimer dissociates into the hydrated
Mg2+ and metal free dimer. (b) The metal-free dimer dissociated into two separate monomers. 〈∆Gbind(a/b)〉 is the binding free energy
for step (a) or (b), respectively, whereas 〈∆Gbind(a+b)〉 is the free energy difference for the overall process (a and b).
a)(endo-S-cdg)2Mg2+(H2O)4 → Mg2+(H2O)4 + (endo-S-cdg)2 b)(endo-S-cdg)2 → 2endo-S-cdg
〈∆Evdw〉 15.23 (4.67) –23.52 (4.11)
〈∆Eele〉 –579.09(14.82) 117.78(7.54)
〈∆Gele,desolv〉 555.91(13.20) –84.42(6.44)
∆Gnp,desolv〉 –1.80(0.09) –3.33(0.26)
〈∆G0bind〉+ 〈∆Gdesolv〉 -9.75(7.16) 6.51(5.66)
〈∆H(a+b)〉 –3.24
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tively.
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PleD (PDB code: 1W25); (b) endo-S-CDG in inactive PleD (PDB code: 1W25); (c) CDG in
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4.3 PleD Dimerization
4.3 PleD Dimerization
Atomic Simulations of PleD with/without c-di-GMP Bound As we mentioned above,
a central question for understanding the function of PleD is its primary function (pro-
duction of c-di-GMP upon PleD dimerization) with self-inhibition by c-di-GMP. Both
I- and A-sites are located in the DGC domain. So far, still little is known about how
DGCs work at a molecular level. For this, one of the works in this thesis is to study
inhibited monomeric PleD and dimeric PleD with and without intercalated c-di-GMP
present in the inhibition site to investigate a possible biological mechanism for allosteric
regulation. All MD simulations were carried out with NAMD using the CHARMM 22
force field. The starting structures were taken from the X-ray structure of the PleD
dimer (pdb code: 1W25, 2V0N/2WB4). The MD simulations were carried out for 2
ns each system (20 ns in the case of c-di-GMP/endo-S-CDG binding PleD monomer).
It has been proposed that binding of c-di-GMP to the PleD monomer and dimer will
eliminate catalytic activity by domain immobilization.4 Moreover, inhibition (I-site) and
the active site (A-site) of PleD are dynamically coupled through an network of atomic
motions that involves the β2 strand (direct coupling with DGC, pathway I) and the
structural elements β3, α2 and α3 of DGC (network coupling, pathway II).196,199 To
obtain information on the proposed pathway and to discriminate these two pathways,
longer simulation and further analysis are required.
Atomic Simulations of c-di-GMP/endo-S-CDG Bound to DGC Domain To verify
that DGC domain is sufficient for feedback inhibition and to exclude path II, DGC
domain of PleD individually (excluding D1/D2) with c-di-GMP and endo-S-CDG bound
were investigated. All MD simulations were carried out with NAMD using the CHARMM
22 force field for 20 ns each trajectory.
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Atomic Simulations of Phosphorylation of D1/D2 Domain The DGC activity of PleD
is activated upon phosphorylation of D1/D2 domain. Phosphorylation of D1/D2 domains
invokes repacking of the D1/D2 loop region, and promotes PleD dimerization.4,184,193 A
lot of study has been performed for the mechanism of CheY-like domain (PleD) activity
upon phosphorylation:35,200 a major repositioning of the β4 - α4 loop and the reorienta-
tion of the sidechain of a conserved Tyr/Phe residue from solvent exposed to a buried
position; repositioning of the Thr/Ser due to hydrogen-bond formation leaves more space
for the Tyr/Phe to addopt the buried rotameric state. However, still, detail structural
changes associated with the β4 - α4 loop relaxation from the active to its inactive form,
interface changes and interaction between monomers when dimerization happens are
still unknown. Four systems were investigated: D1/D2 with and without beryllofluoride
binding in inactive PleD (pdb code: 1W25 and 2V0N). All MD simulations were carried
out with NAMD using the CHARMM 22 force field for 2 ns each trajectory.
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Chapter 4 presented the work of the ubiquitous second messenger c-di-GMP which
regulates cell surface-associated traits and biofilm formation. Biofilm formation is
involved in life-threatening infectious diseases such as cystic fibrosis and the colonization
of medical devices.
Another case of protein dimerization which leads to a common disease (diabetes)
is insulin. Insulin is a hormone, which is produced in the pancreas as a hexamer and
is a main regulator of the glucose levels in the blood. When we eat, glucose levels rise,
and insulin is released into the bloodstream as a monomer. The insulin acts like a key,
opening up cells so they can take in the sugar and use it as an energy source. Usually
insulin dissociates from its hexameric storage form through an intermediate dimer state
to the bioactive monomer before binding to its transmembrane insulin receptor. The
interface which the insulin monomer uses to bind to the receptor, is the same one that
forms the dimer and hexamer. Thus, once the monomers form dimers or hexamers, they
can not bind to the receptors and subsequently, lose their biological function which lead
to diabetes.
Many detailed questions concerning the stability of aggregated insulin, the confor-
mation of inactive and active native and mutated insulin monomers, designing insulin
mutants which keep the active conformation but have lower aggregation ability still need
to be resolved. Although extensive research on insulin has been conducted, more efforts
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are still needed and provide new progress in insulin treatment. The following manuscript
is in preparation.
5.1 Influence of Mutations at Position B24 on the Stability of
the Insulin Dimer
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Introduction
Insulin is a small protein that plays an eminent role in controlling glucose uptake in cells.1
The crystallized, native hormone is a hexamer and consists of two trimers with either two or
four zinc atoms bound to it. Each dimer contains two monomers (chain A with 21 amino acids
and chain B with 30 amino acids) which are connected by two interchain (CysA7–CysB7 and
the other from CysA20–CysB19) and one intrachain (CysA6–CysA11) disulphide bond. Un-
der physiological conditions, insulin monomers readily aggregate to dimers. The interactions
stabilizing the native dimer are predominantly nonpolar2–4 with the β -sheet hydrogen bonds
mainly replacing water-hydrogen bonds and contributing to orienting the two monomers. One
possibility to prevent aggregation is to modify the complexation interface.3 It is known that the
sequence and structure of insulin is intimately linked to its biological function. However, since
the structure of the complex formed by insulin and its receptor is unknown, the study of the
binding process at an atomistic level, even by theoretical means, can not be addressed. When
insulin is mutated, the resulting change in its activity (increase or decrease) may be due to mod-
ification of the insulin/receptor interactions, to a change of the insulin fold required for binding
to the receptor5 or to altered pharmacokinetics.
Insulin shows an important propensity to aggregation. Although it circulates in the serum and
binds to its receptor in its monomeric form, insulin self-associates to dimers at micromolar con-
centrations, and in the presence of zinc ions it further assembles to hexamers.6 This strongly
affects the physiological function and pharmacokinetics of the hormone. When associating to
dimers, the extended C-terminal ends of the two B-chains are brought together, forming a two-
stranded antiparallel β -sheet. In the hexameric form, the form in which insulin is stored in the β
cells, the two central zinc ions are coordinated by the B10 histidine residues. Structural studies
of native insulin in the monomeric state are made difficult by self-association. All published
high resolution X-ray structures of insulin are aggregated species except for a partial report of
results for monomeric insulin7 for which no coordinates have been released so far. Thus, the
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current view of insulin structure-function relationship is derived primarily from insulin hexamer
and dimer crystal structures and from studies of the structures and activity of chemically modi-
fied and/or naturally occurring mutant insulins in solution.5,8,9
Many studies suggest that the conformation of insulin found in the X-ray structures (dimer/hexamer)
is inactive and that the separation of the N-terminus of chain A and the C-terminus of chain B
is required for interaction with the insulin receptor.7–15 This separation exposes a hydrophobic
surface including the nonpolar residues Leu(A16), Tyr(A19), Leu(B11) and Leu(B15) and, in
particular, Gly(A1), Ile(A2), Val(A3), which is crucial for insulin binding to its receptor. The
C-terminus of chain B is situated near residues Gly(A1), Ile(A2) and Val(A3) and shields them
from the solvent.
Several NMR studies of active insulin mutants show a rearrangement of the C-terminus end of
chain B.8,14 Also, activity studies of semi-synthetic analogs have found that the C-terminal pen-
tapeptide of the chain B (B26-B30) can be deleted without a decrease in biological potency.15 A
recently published preliminary crystallographic investigation of a low pH native porcine insulin
monomer7 shows that most of the insulin monomer is well ordered and similar in conformation
to other insulin structures. However, residues B21-B25 appear to have multiple conformations,
whereas the C-terminus of chain B is highly flexible when not involved in dimer formation
(electron density for B25-B30 is essentially absent). A Raman spectroscopy and microscopy
study of insulin in different aggregation states (monomer, dimer, hexamer and fibril) shows that
dimerization damps fluctuations at an intermolecular β -sheet.16 Experimental alanine scanning
finds that substitution of alanine at various positions reduces insulin affinity for the receptor by
more than 20-fold.17 The residues that are most likely to be directly involved in binding are
A1, A2, A3, A19, B12, B23, and B24. Any substitution of residues A1-A3 has been shown to
impair function.15
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Figure 1: Structure of insulin dimer (PDB Code: 4INS). Chain A (blue), Chain B (red), Chain
C (grey), Chain D (orange). β -turn (residue 20-23) and residue 24 are shown as stick represen-
tation in green and iceblue respectively.
Phenylalanine at position B24 is invariant among insulin sequences and is located at the dimer-
ization interface and maintains the orientation of the B-chain of the monomer.8,18 These ob-
servations together with studies of low-potency B24 analogues suggest that PheB24 plays an
important role in the activity of insulin. SerB24 and LeuB24 analogues show reduced binding
potency.19 However, it was also found that certain B24 substitutions, such as glycine20 and
D-Ala,11 are well tolerated in view of insulin affinity to its receptor. Their bioactivity has also
been referred to as “anomalous” as it can not be readily explained by crystal models. The role
of PheB24 in stabilizing the insulin dimer has also been studied to some extent. It was found
that unlike native insulin, the GlyB24 mutant does not dimerize in aqueous solution at pH 1.9.8
Furthermore, alanine scanning of the dimerization interface revealed that the AlaB24 mutant is
a monomeric insulin and does not readily aggregate. This suggests that the AlaB24 and GlyB24
4
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mutant dimers are less stable than the native dimer.
In the present work the dynamics and stability of the native and four B24 mutant insulin dimers
(AlaB24, GlyB24, D-AlaB24, Des-B25) were investigated by using computer simulations. Pre-
vious studies have shown that computer simulations provide meaningful and complementary
information to experimental characterizations.4,21,22 For the native insulin dimer experimental
data on the dimerization energy (−7.2 kcal/mol in favour of the dimer23) is available which
provides a validation for the simulations. The work is structured as follows. First, the computa-
tional methods are presented. Then results on the dimerization energies and internal dynamics
of insulin monomers and dimers are reported. Finally, the results are discussed in light of ex-
perimental data.
Computational Methods
Molecular dynamics simulations
Molecular dynamics (MD) simulations were carried out using CHARMM24 (version 35b1) and
the "all-atom" CHARMM2225 force field with periodic boundary conditions (PBC).26
Native and Mutant Insulin Monomer:
The starting coordinates for the MD simulations were the X-ray structure of the native porcine
insulin dimer resolved at 1.5 Å (Protein Data Bank (PDB27,28), Code: 4INS.29 The structure
contains the coordinates of the insulin dimer and two aggregated zinc atoms. As the zinc
atoms play an important role only in the hexamer formation they were moved for this inves-
tigation. Hydrogen atoms were added to the X-ray structure. The crystal structure was also
used to generate mutants computationally. The Phenylalanine at position B24 was mutated into
Glycine (Gly), Alanine (Ala), and D-Alanine (D-Ala) which yields mutants B24Gly, B24Ala,
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and B24D-Ala, respectively. Besides, wildtype insulin dimer without the Phe(B25) amino acid
on both monomers, Des-B25 mutant is also studied here.
Native and Mutant Insulin Dimer:
For the simulation of the insulin dimers the same X-ray structure (Protein Data Bank (PDB27,28),
entry 4INS29 was used. The wildtype dimer and mutants were solvated in a 77.6 × 62.8 × 55.8
Å box of TIP3P water molecules. Water molecules overlapping the protein were removed which
leads to a system with approximately 1550 protein atoms and 8495 water molecules. The sol-
vent was equilibrated at 300 K during 30 ps with the insulin kept fix. Then 2000 steps of steepest
descent (SD) minimization were carried out. The entire system was heated to 300 K during 15
ps using harmonic constraints with a force constant of 5 kcal/molÅ2 on the position of the back-
bone atoms. The system was further equilibrated for 120 ps with gradually decreasing harmonic
constraints (from 5 kcal/molÅ2 to a fully unconstrained system) on the backbone atoms. For all
simulations the Verlet leapfrog integrator was used for time propagation with a time step of 1 fs.
A 12 Å cut off was applied to the shifted electrostatic and switched Van der Waals interactions
and images for periodic boundary conditions were updated every 10 time steps. All distances to
hydrogen atoms were constrained by using SHAKE.30 For the native system simulations of 15
to 20 ns in length were carried out to verify earlier results.21 For wildtype dimer and mutants
(B24Gly, B24Ala, B24D-Ala, Des-B25) nine individual trajectories were run starting from dif-
ferent structures taken from the equilibration run. In the following the trajectories are labeled
by letters to indicate the amino acid at position B24 (F for Phenylalanine , A for Alanine and G
for Glycine) and numerals indicate the starting structure. The trajectories are labeled by double
letters for the mutation and a numeral for the run.
6
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Calculation of the Binding Free Energy
The binding free energy ∆Gbind for a dimer consisting of two monomers can be calculated
by considering a thermodynamic cycle and using the molecular mechanics-generalized Born
solvation model (MM-GBSA).31 For details the reader is referred to Ref.4 Here only a short
description of the main steps involved in calculating ∆Gbind is given. ∆Gbind can be separated in
two terms, the entropic and the enthalpic contribution. In this approach the binding free energy
∆Gbind is calculated as the sum of the average (indicated with brackets) gas phase energy ∆G0bind,
the desolvation energy of the system ∆Gdesolv and an entropic part −T ∆S:
∆Gbind = 〈∆G0bind〉+ 〈∆Gdesolv〉−〈T ∆S〉 (1)
Enthalpic Contribution: The enthalpic contribution ∆Genthalpic to the binding free energy and
was calculated using equation 2.
∆Genthalpic = 〈∆G0bind〉+ 〈∆Gdesolv〉 (2)
where ∆G0bind is the sum of the intramolecular contribution ∆Eintra, the Van der Waals term
∆EvdW and the electrostatic contribution ∆Eelec. The Van der Waals and electrostatic interaction
energy between the two monomers were calculated together with the difference in internal en-
ergy between the dimer and the two isolated monomers. Because the calculations were carried
out with the "same trajectory method" (STM) where the monomeric and dimeric contributions
were taken from the same trajectory, the difference of the internal energy cancels.
∆Gbind = ∆EvdW+∆Eelec (3)
This method is expected to give more stable results than analysis of different trajectories for the
monomers and the dimer.4 The contribution ∆Gdesolv is the difference between the solvation
energy of the dimer and the solvation energies of the isolated monomers: ∆Gdesolv = ∆Gdimersolv −
7
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(∆Gmonomer1solv +∆Gmonomer2solv ). Each term can be separated into an electrostatic part ∆Gsolv,elec
and a non polar contribution ∆Gsolv,np.
∆Gsolv = ∆Gsolv,elec+∆Gsolv,np (4)
The nonpolar contribution to the solvation free energy is assumed to be proportional to the sol-
vent accessible surface area (SASA). This approximation is often used and is justified by the fact
that the solvation energy of saturated non polar hydrogen bonds is related to the SASA through
∆Gsolv,np = 0.0072× SASA.31–33 The solvent accessible surface areas were calculated ana-
lytically with CHARMM. The ∆Gsolv,elec was calculated with the generalized Born GB-MV2
model as implemented in CHARMM which is much faster than solving the Poisson equation
and makes it applicable to a large set of structures. All enthalpic contributions were calculated
using a distant dependent dielectric with ε = 1, a 12 Å cutoff for Van der Waals and electrostatic
interactions. In the GB-MV2 model the expression of Still et al.33 is used to calculate ∆Gsolv,elec.
∆Gsolv,elec = k∑
i j
(qiq j/
√
r2i j +αiα je
−r2i j/Ksαiα j) (5)
with k = −166.0(ε−1solute− ε−1solvent), εsolute and εsolvent are the dielectric constants of the solvent
(εsolvent = 80 for water) and the solute (εsolute= 1 for the protein). αi, αj are the Born radii of the
atoms i and j and Ks = 8 which is different from the original Still expression, where Ks = 4. All
enthalpic terms were calculated for frames taken every 4 ps of the trajectory.
Entropic contribution: The entropic contribution to the binding free energy was separated in
translational, rotational and vibrational parts as seen in equation 6. The total entropic contribu-
tion is the sum of three parts, which were calculated separately.
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−T ∆Stotal =−T ∆Strans−T ∆Srot−T ∆Svib (6)
Each of the terms is calculated using standard formulae from statistical mechanics.34 For the vi-
brational contribution to the free energy, snapshots were taken every 100 ps along the trajectory.
These structures were minimized by 10000 steps of SD minimization and followed by ABNR
minimization until the root-mean-square of the energy gradient reached 10−5 kcal/mol/Å . All
calculations were carried out with a distant depending dielectric with ε = 4. From these min-
imized structures the normal mode frequencies were calculated with the VIBRAN module im-
plemented in CHARMM. A cutoff of 12 Å for the non bonded interactions and the distance
dependent dielectric constant was set to ε = 4 as for the structure minimization. The dimeriza-
tion energy was then calculated by taking the difference between the energy of the dimer and
two times the value calculated for the monomer.
Dynamical Cross Correlation Maps
Dynamical cross correlation maps quantify the coupling between different residues during an
MD simulation. The cross correlation coefficient Cij of residues i and j is given by
Ci j =
〈∆ri∆r j〉√
〈∆r2i 〉〈∆r2j 〉
(7)
where ∆ri and ∆r j are the displacements of the backbone atoms from the reference position. Ci j
varies between 1 and −1, where 1 corresponds to movement in the same direction (correlated)
and −1 movement in the opposite direction (anti-correlated). In a dynamical cross-correlation
map (DCCM), motion in the same direction (correlated) can be found in the upper left triangle,
while motion in opposite directions (anti-correlated) is in the lower right panel. Typically, corre-
lated motions are much more pronounced than anti-correlated motions. α-helices are manifest
as a broadening of the diagonal while β -sheets appear off-diagonal (ascending for parallel, and
9
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descending for anti-parallel β -sheets). It should be noted that DCCM do not give information
about the magnitude or the direction of the motion. The calculated cross correlations were av-
eraged over windows of different length. Windows of 50 ps were chosen to evaluate along the
calculated timescale for each trajectory separately.
Results and Discussion
First, the structures of the native and mutant insulin monomers and dimers are characterized.
Then, the dimerization energies of the native and mutant proteins are compared and discussed at
an atomistic level. Finally, the results are discussed in the context of experimental and previous
simulation results.
10
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Dynamics of the native and mutant insulin monomers
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Figure 2: RMSD along the trajectories for the backbone atoms of the native and mutant insulin
monomers. (A) Wildtype (B) B24Gly (C) B24Ala. Alanine substitutions (alanine scanning
mutagenesis) are one of the standard procedures (most conservative mutation) to interrogate
protein stability35,36 or protein function5 upon changing the amino acid sequence of a protein.
(D) B24D-Ala (E) B24Des-B25. Black: RMSD of the entire protein superimposed by the
backbone of the protein. Red: RMSD of the entire protein superimposed by the backbone
atoms of helices (residue 1 to 8 of chain A, residue 12 to 18 of chain A, and residue 9 to 19 of
chain B).
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The Native monomer: The insulin monomer shows a RMSD relative to the initial X-ray struc-
ture of around 3 Å. This is indicative of a high degree of flexibility and was already observed
in previous simulations.21 The transition in the present work already occurs during the equi-
libration phase and is therefore not visible in the RMSD(t) curves shown in Figure 2a). The
black trace corresponds to superimposing the backbone atoms whereas the red trace measures
the RMSD for the helices only (residues 1 to 8 and 12 to 18 of chain A; residues 9 to 19 of
chain B). Both RMSD are quite close to each other, which means that the RMSD changes of
the entire monomer is caused by the C-terminal of chain B or/and N-terminal of chain A.
The GlyB24 monomer: The RMSD fluctuations for the GlyB24 mutant are considerably dif-
ferent from those of the native dimer. 2-dimensional NMR experiments have suggested that
residues B19-B30 of the C-terminal part have a distinctly different structure than that of native
insulin.8 GlyB24 is an insulin analog which maintains considerable biological activity (22 %
and 78 % potency relative to native insulin, respectively11,37) compared to the native hormone
even though NMR studies suggest complete loss of the characteristic B-chain β−turn8 which in
native insulin allows the extended B-chain C-terminal region to fold against the central B-chain
helix. Fluorescence anisotropy studies of the GlyB24 mutant (with an additional TrpB25 muta-
tion) found partial maintenance of the B-chain β−turn under near-physiological conditions.38
It is interesting to note that the B-chain β−turn has been found to be maintained in all crystal
structures except for one structure8 where this β−turn was absent. It is possible that the exper-
imental conditions (pH 1.9), under which the original NMR studies were carried out, contribute
to the observation of this unusual structure.8,38
The AlaB24 monomer: For the Alanine mutant also a departure from the monomer structure
in the native dimer is observed. Typical RMSDs are around 3 Å with occasional excursions to
up to 4 Å. This is between the behaviour found for the native and the GlyB24 monomer. The
structure of the AlaB24 mutant monomer has not been characterized experimentally. However,
12
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this mutant shows a lower propensity for dimerization39 (vide infra) which makes it interest-
ing for the discussion in the present context. Also, insulin analogs with PheB24 replaced by
biphenylalanine have recently been synthesized and characterized.40
The D-AlaB24 monomer: It was found that substitution with D-Alanine at position B24 leads
to a very active insulin (affinity of 150 % relative to native insulin).11 The structural changes
found in the present simulations indicate that the monomer deviates from the reference native
monomer structure quite rapidly but does not show much different behaviour than the native or
AlaB24 monomer.
The Des-B25 monomer: Finally, the RMSD from the starting conformation of the native insulin
monomer during the 10 ns MD simulation, are calculated for the entire protein superimposed
by the backbone of the protein (black line) or superimposed by the helices . As expected, the
Des-B25 monomer is considerably flexible with RMSD value around 4 Å, and sometimes even
up to 6 Å during the trajectory (see Figure 2e). The absence of B25 residue may cause the
β−sheet to unfold, which is part of dimer interface. This agrees with the smaller dimerization
free energy of Des-B25 dimer (vide infra) compared to native insulin. In previous work by
Jørgensen et al.,2 they found that the C-terminal end of the B-chain packs closer against the
rest of molecular in des-B25 monomer. Compared to native insulin monomer, deletion of the
B25 residue shifts the hydrophobic ProB28 residue to position B27, subsequently turns the hy-
drophobic side-chain of this residue away from the surface and to position B chain α-helix of
the monomer and eliminate the hydrophobic surface at the C-terminal end of the B-chain.
Dynamics of the native and mutant dimers
To assess the stability of the simulations for the dimers, the RMSD for backbone atoms of entire
protein and backbone atoms of the helical regions (A2 to A9, A14 to A20 and B9 to B19) along
13
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all trajectories was calculated.
The RMSDs for backbone atoms of wildtype dimers and insulin mutants (SI-Figure 1) were
calculated vs. X-ray native insulin structure show that for WT insulin, the RMSD of the entire
protein is well within 2 Å. Hence, the WT insulin is stable in its dimeric form. The RMSD
of the B24Ala mutant are indicative of more flexible structures whereas the RMSD of B24Gly
and B24D-Ala are ≈ 3 Å and the RMSD of Des-B25 insulin dimer is large since the structures
change dramatically during the simulation.
Dynamical cross-correlation maps (DCCM) allow to analyze persistent, (anti-)correlated mo-
tions of residue pairs from the MD simulations and serve as a quantitative measure for the
collective motion in a protein. The helices extend from residues A2-A8, A13-A19, and B9-
B19 and the disulfide bonds are located between residues (A6,A11), (A7,B7), and (A20,B19).
Correlated motions between the A- and B-chain are quite similar for the native, AlaB24, and
GlyB24 whereas they are considerably reduced for the D-AlaB24 and Des-B25 mutant. In par-
ticular, the correlation of the residues on the dimer interaction interface B24-D26, B25-D25 and
B26-D24 of the Des-B25 mutant are much lower, which will affect the dimerization free energy
of Des-B25 mutant dimer, as shown below.
The Native dimer: In Figure 3, the DCCMs for the native and mutant insulin dimers are shown.
Most of the strong correlations have their origin in structural features such as disulfide (A7-B7,
A20-B19, and A6-A11) or hydrogen bonds. In all DCCMs it is evident that the two monomers
are not equivalent because the C-termini of the two B-chains have different conformations. For
monomer II, correlated motions between A1 and B30 are found which are weaker or absent for
monomer I, as the conformation is different and does not allow for interaction between these
residues. The only appreciable correlation between the two insulin monomers are between the
C-termini of chains B1 and B2 (residues B41 to B51) which constitutes the dimerization inter-
14
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face. In particular, residues B24 to B26 are correlated and it has been found that these residues
contribute considerably to the stability of the insulin dimer.4,22 Superposition of selected snap-
shots reveals a compact structure of the native dimer. This is also reflected in the RMSD along
the trajectory. It is interesting to note that - except for the fluctuations at the end of the B-chain
- the RMSDs for monomer I in the dimer and in the monomer are comparable in magnitude.
However, the RMSD-pattern differs and fluctuations around the average are larger in monomer
II than in monomer I.
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Figure 3: Dynamical cross-correlation maps for wildtype (A), B24Gly-SI (B), B24Gly-WI (C)
and B24-Des-B25 (D) insulin dimer. The correlation coefficient are averaged over windows
of 50 ps. Positive cross-correlated coefficients are collected in the upper-left triangle. Only
cross-coefficients larger than 0.30 are shown. The color code is: red: Cij = 0.30−0.40; orange:
Ci j = 0.40−0.5; yellow: Cij = 0.5−0.6; green: Ci j = 0.60−0.70; deep green: Cij = 0.7−0.8;
cyan: Cij = 0.8−0.9
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The GlyB24 dimer: The DCCM for this mutant is comparable to the one for the AlaB24 mu-
tant dimer. However, the two correlations (TyrB26(I)–AsnA21(II) and CysA20(I)–ProB28(II))
are stronger, whereas the GlyA1(II)–AlaB(30) correlation is weaker. The superposition of se-
lected structures shows more variability compared to the native dimer than the AlaB24 mutant
whereas the RMSD are qualitatively similar. The fluctuations in the RMSD of monomer II are
larger whereas RMSD and its fluctuations in monomer I are comparable to those of the native
and the AlaB24 mutant. The Ramachandran plot of the β -turn in GlyB24 (see Figure 4b) shows
that compared to wildtype insulin, the β -turn (residues 20 to 23) of the GlyB24 undergoes more
structural changes especially for residue 23 (black trace). Moreover, the Ramachandran plot of
the β -sheet (residues 24 to 28) in GlyB24 also experience larger structural changes. Residue
Pro28 switches between two conformations and the structure of residue 24 fluctuates more
which may affect the structure of the β -turn. To further study the structural changes upon the
mutation by Glycine, we investigated the pesudodihedral angle (four successive CA atoms) of
the β -turn and the β -sheet. (see Figure 6 in the SI). Compared to the native insulin dimer (SI-
Figure 6a), the β -turn (black peak) samples a wider range of the pseudo-dihedral in the B24Gly
mutant.
The AlaB24 dimer: The correlated motions include all the ones already found for the native
dimer, although with slight differences in their intensity. Correlations around the disulfide
bonds are somewhat larger as is the correlation between the C-termini between chains B1 and
B2. More significantly, an additional correlation between TyrB26(I) and AsnA21(II) was found
which is only weak in the native dimer. The superimposed structures are less compact than the
native dimer although the RMSD fluctuations are quite similar. Differences are found in the
C-terminal regions of monomers I and II. In particular, the C-terminus of monomer II is pushed
towards chain A. Again, the two monomers are found to behave differently and the fluctuations
around the mean are larger for monomer II than for monomer I.
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The D-AlaB24 dimer: Compared with the native insulin dimer, the DCCM of the D-AlaB24
calculated from all eight independent trajectories shows that there are weaker interactions be-
tween residue 24 of chain B (B24) and residue 26 of chain D (D26). This hydrogen bond
interaction between B24 and D26 is one of important interactions at the dimerization interface
and contributes to the dimerization free energy of the dimer. The RMSD of backbone atoms of
the D-AlaB24 dimer is stable with slightly larger amplitudes compared to native insulin dimer
(see Figure 1d in the SI). In the Ramachandran plot of the C-terminal of chain B, Figure 4d), it
is found that the Φ value of the D-Alanine residue (black trace) covers a wider conformational
range compared to AlaB24 and the wildtype insulin dimer. Moreover, the residue 26 (blue
trace) suggests that two conformations are present and the conformation of the C-terminal of
chain B is changing accordingly. For the wildtype insulin, the PheB24 aromatic ring stabilizes
the β -turn (residue B20 - B23) structure by packing against residue 19. When residue 24 is
substituted by D-Ala the structure of the β -turn is more flexible during the trajectory with the
larger fluctuation area of [Φ, Ψ] for all 4 residues in the β -turn.
The Des-B25 dimer: The cross-correlation map of the Des-B25 insulin mutant (see Figure 3d)
shows that there is no or little correlated motion between B24 and D26. This is related to
the loss of H-bonding interaction between B24 and D26 as the deletion of B25 changes the
monomer-monomer interface and leads to two weakly interacting monomers. The RMSD of
Des-B25 dimer is larger than all other four insulin mutants, around 4 Å as is shown in SI-Figure
1. As already discussed for the monomers, in the Des-B25 mutant the hydrophobic side-chain
of ProB28 can interact with the hydrophobic surface formed by residues ValB12, GluB13, and
LeuB15. The structure reveals that the lost ability of Des-B25 insulin to self-associate is caused
by a conformational change of the C-terminal region of the B-chain. Des-B25 insulin does
not form the anti-parallel β−sheet between two monomers that characterizes the insulin dimer.
This is primarily found for the C-terminal end of the B-chain which packs closer against the rest
of the molecule in the Des-B25 monomer than in the monomers of the dimeric porcine insulins.
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Deletion of the PheB25 residue not only moves the hydrophobic ProB28 residue to position
B27, it also results in an intra-molecular hydrophobic interaction between Pro(B28) and the hy-
drophobic region LeuB11-LeuB15 of the B-chain α−helix. This interaction interferes with the
inter-molecular hydrophobic interactions responsible for the dimerization of native insulin, de-
priving the mutant of the ability to dimerize. It results in an intra-molecular hydrophobic inter-
action between Pro(B28) and the hydrophobic region LeuB11-LeuB15 of the B-chain α−helix.
This interaction interferes with the inter-molecular hydrophobic interactions responsible for the
dimerization of native insulin, depriving the mutant of the ability to dimerize.2
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Figure 4: Ramachandran plot of β− turn (residue 20 to 23) of (a) wildtype insulin dimer (b)
GlyB24 insulin dimer (c) AlaB24 insulin dimer (d) FB24D-Ala insulin dimer (e) Des-B25 in-
sulin dimer during 10 ns trajectory length. One dot per ps, 10000 dots for each residue. Black
is for B20Gly, red for B21Glu, blue for B22Arg, and green for B23Gly.
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Dimerization Energy Calculation
A central aspect of the present work is the calculation of the relative stabilities of mutated in-
sulin dimers relative to that of the native dimer. Experimentally, a value of −7.2 kcal/mol in
favor of the dimer was determined41 for native insulin which compares with ∆Gbind = −11.9
kcal/mol (absolute binding free energy) and 〈∆G0bind〉+ 〈∆Gdesolv〉=−38.7 kcal/mol (enthalpic
contribution to ∆Gbind ) from molecular dynamics simulations,4 where ∆Gbind = 〈∆G0bind〉+
〈∆Gdesolv〉−T ∆S.
Table 1: Binding Free Energy for the Dimerization of insulin and Contributions of Solvation,
van der Waals, and Electrostatic Interactions and Entropic Terms, using the Same Trajectory
Method (kcal/mol)
WT Gly Ala D-Ala Des-B25
〈∆Evdw〉 -66.59(4.36) -53.39(4.35) -56.85(4.19) -60.39(5.06) -44.47(5.21)
〈∆Eele〉 -114.38(34.28) -107.84(40.75) -91.79(35.53) -104.85(33.88) -56.15(32.19)
〈∆Gele,desolv〉 146.23(32.58) 132.83(38.36) 120.17(34.27) 142.77(30.85) 92.43(29.57)
∆Gnp,desolv〉 -10.28(0.61) -9.76(0.49) -9.89(0.42) -10.54(0.48) 7.99(0.61)
〈∆G0bind〉+ 〈∆Gdesolv〉 -45.02(6.46) -38.16(7.27) -38.36(7.49) -33.00(9.47) -16.19(6.47)
〈∆Strans〉 14.98 14.98 14.98 14.99 14.98
〈∆Srot〉 13.94 13.82 13.85 13.82 13.82
〈∆Svib〉 3.82 1.48 - 0.58 - 1.14 - 1.70
−T 〈∆S〉 32.74 30.28 28.26 27.67 27.11
〈∆Gbind〉 -12.3 -7.9 -10.1 -5.3 10.9
The enthalpic contribution Genthalpic =EvdW+Eelec+Gsolv,elec+Gsolv,nb is a first quantity which
allows to qualitatively compare the stabilities of the different dimers relevant in the present
study. For the native structure 〈∆G0bind〉+ 〈∆Gdesolv〉 (∆G0bind is the gas phase contribution to the
binding free energy ∆G0bind = ∆Hgas−T ∆Sgas) from the two trajectories is ≈−45±5 kcal/mol
which is reduced to −38± 6 kcal/mol for the AlaB24 mutant and ≈ −40± 7 kcal/mol for the
GlyB24 mutant. From all three systems investigated the native protein forms the most stable
dimer. The Gly mutant dimer is less stable than the native protein by 5 kcal/mol and the Alanine
mutant is destabilized by 7 kcal/mol with respect to the native structure. These destabilizations
compare with a stabilizing enthalpic contribution of the two phenylalanine residues at position
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B24 which has been calculated to be −3.92 and −2.68 kcal/mol, respectively.4
The Native dimer: Wildtype insulin dimer is enthalpically stabilized by ≈−45 kcal/mol as cal-
culated from all the 15 trajectories with 10 ns for each trajectory, see Table 1. In Table 1, all the
mutants have lower binding free energy compared to the wildtype insulin dimer which suggests
that these dimers are less stable. As the absolute binding free energy of wild type insulin is
−7.2 kcal/mol and as we do not expect that differences in going from relative to absolute bind-
ing free energies are greatly affected, one already can conclude that all mutant dimers are only
marginally stable.
The B24Gly dimer: As shown in Table 1, the absolute dimerization free energy is around −8
kcal/mol with the entropy contribution around 30 kcal/mol. The loss of translation and rota-
tion and vibration entropy due to dimerization process indicate that the process is entropically
highly unfavorable. However, the more negative enthalpy value propose that the dimerization
is driven by the enthalpy contribution. For the GlyB24 dimer, two types of situations are found
in the simulations. In one of them the GlyB24 monomers interact with each other with a sim-
ilar strength as the WT dimer, i.e. ∆ ≈ −43 kcal/mol. In the other case, the GlyB24 dimer is
destabilized by 20 kcal/mol compared to the WT dimer. (Detail discussion will be listed later.)
The B24Ala dimer: The absolute dimerization free energy of B24Ala mutant dimer is about
−10 kcal/mol averaged from all the trajectories. Compared to B24Gly, the dimerization free
energy of B24Ala are relative more negative (favoring association), which may due to the side-
chain of alanine is larger in size and more hydrophobic.
The B24D-Ala dimer: The average absolute dimerization free energy of B24D-Ala mutant
dimer from 10 trajectories is around −5 kcal/mol. (See Table 1) This is in line with the conclu-
sion we got from the structure that D-Ala substitution has more flexible structure and a bit more
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favorable in monomer form compared to native insulin.
The Des-B25 dimer: Des-B25 mutant dimer has a positive dimerization free energy of around 11
kcal/mol with the contributions of enthalpy (−16 kcal/mol) and entropy (27 kcal/mol). Table 1
the positive dimerization free energy value indicates that Des-B25 mutant dimer has dramatic
structure changed, and are monomeric form favored. This is in line with what we observed in the
structure characters. Compared to native and other mutant insulin dimer, the vibration entropic
part is relative larger but still can not compensate the lost translational and rotational motion.
Meanwhile the enthalpic is relative unfavorable, which may due to the loss of two hydrophobic
surfaces as we discussed before for dimerization compared to native and other mutants.
To better characterize the structural changes along a trajectory, the secondary structural ele-
ments analyzed for each snapshot in a 10 ns simulation are reported in Figure 5. For both,
wildtype and mutant insulin dimer, the structure component of monomer I and monomer II
along the trajectory are not identical. This is particularly evident for the AlaB24 and D-AlaB24
mutants, see Figure 5c and d. In the AlaB24 mutant, residues 12 to 18 form a 3-10 helix or a
turn in monomer I instead of a α− helix as in monomer II. In the D-AlaB24 mutant, residues 20
to 23 of chain D in monomer II form a 3-10 helix instead of a β−turn in monomer I. Secondly,
there are different structural components between wildtype and mutant insulin dimers. This
is mainly found by considering the helix (residues 13 to 19) of chain B, which indicates that
residue 24 interacts closely with residues on helix of chain B, whereas substitution at position
B24 will affect the structure around the β−turn (residues 20-23). Moreover, in D-AlaB24 there
is a turn formed by the C-terminal of β−sheet of chain B in monomer I and the N-terminal of
the α−helix of chain A in monomer II. This demonstrates that there is a major structural change
for the D-AlaB24 mutant dimer, and the turn between chain B of monomer I and chain A of
monomer II causes the structure changed accordingly but not contribute to dimer binding affin-
ity, which maybe another evidence that the dimerization free energy is contributed mainly by
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residues on the monomer-monomer interface. In the Des-B25 mutant the N-terminal β−strand
in chain B of monomers I and II are not extended configuration anymore but more disordered
compared to other mutants or the wildtype insulin dimer.
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Figure 5: Time vs. structural component of (a) wildtype, (b) FB24G, (c) FB24A, (d) FB24D-
Ala, (e) Des-B25 insulin dimer. Green represents Turn, yellow represents extended configu-
ration, light green represents isolated bridge, pink represents alpha helix, blue represents 3-10
helix, and red represents pi-helix.
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The B24Gly Mutant
For the GlyB24 dimer, two types of situations are found in the simulations. As these observa-
tions may also be relevant for understanding the stabilization found in the wild type and other
mutant insulins, these aspects are discussed in more detail in the following. The simulations
analyzed so far show that either the GlyB24 dimer interacts almost as strongly as the WT dimer
(∆G≈ 43 kcal/mol) or that the dimer is considerably destabilized by almost 20 kcal/mol relative
to the WT dimer. These two situations are labelled “weakly” and “strongly” interacting (WI and
SI) dimers, respectively.
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Figure 6: The Electrostatic interaction energy between B13Glu and all other residues on the
B24Gly mutant insulin dimer. (A): B24Gly-SI while (C): B24Gly-WI; (B)-(D) are the distances
between the hydrogen bond donor and acceptor on residue B13Glu and residue B10Hip. red
line: the distance between OE1-B13Glu and N1-B10Hip; black line: the distance between
OE2-B13Glu and N1-B10Hip along the trajectories.
Detailed analysis of the per-residue contributions and the average interaction energies of sidechains
26
5 Computational Characterization of the Insulin Dimerization
122
with their neighboring sidechains shows that these differences mainly arise from contributions
of the electrostatic interaction < Eelec > and solvation energy < Gelec,desolv > . We found that
for wildtype insulin and the SI-GlyB24 mutant the per-residue binding free energies shared
more similarity while for the WI-GlyB24 they per-residue contributions differ. One residue that
contributes much to the difference between SI and WI is GluB13 (see Figure 7), specifically
in terms of the electrostatic interaction. To further explore this, we studied the electrostatic
interaction energy between GluB13 and the surrounding residues for WI and SI-GlyB24 (see
Figure 6). Figure 6a,c reports the electrostatic interaction energy between GluB13 and all other
residues for two different trajectories. In one trajectory (pink, SI) Eelec ≈ −50 kcal/mol while
in the trajectory corresponding to the WI dimer Eelec ≈ −80 kcal/mol. Structurally, this can
be related to a hydrogen bond between GluB13O and HisB10H, as is shown in Figure 6b,d.
This H-bond will lead to a monomer-self-interaction which eliminates it from the dimerization
energy and reduces the solvation energy and partially explains the difference between the two
types of behaviors of the GlyB24 mutant.
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Figure 7: Per-residue contribution to the total dimerization free energy of wildtype insulin(A),
B24Gly-mutant-WI (B) and B24Gly-mutant-SI (C). X axis is the residue number, 102 in total
for insulin dimer; Y axis is the dimerization free energy in kcal/mol.
To further explore this effect, additional analysis of the per-residue contributions (see Figure 8)
is carried out. The dimerization free energy is dominated by contributions from chains B and
D. Particularly large differences between WI and SI are found for residues 22 to 26 of chain B
and residues 19 to 26 for chain D. A comparison of WT and a WI-GlyB24 trajectory is shown
in Figure 8. The left panel reports the difference in per-residue contribution to the total ∆G for
chain B whereas the right panel corresponds to chain D. For both chains, 20 % of the difference
is for the first 20 residues whereas the remaining 10 residues contribute 80 % to the difference.
Further analysis shows that the backbone of chain B contributes more to ∆∆GWT/GlyB24 than
the side-chain by ≈ 3 kcal/mol, whereas for chain D the contributions are about equal.
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Figure 8: The difference of per-residue contribution to the total dimerization free energy from
wildtype insulin and B24Gly-mutant-WI insulin. (A) The difference between chain B of WT
and chain B of B24Gly-mutant-WI. (B) The difference between chain D of WT and chain D
of B24Gly-mutant-WI. Black line: all atoms on chain B; red line: backbone atoms; green line:
sidechain atoms. X axis is the residue number, 30 in total for chain B and chain D respectively;
y axis is the dimerization free energy in kcal/mol.
The RMSD for the backbone of residues 22-26 of chain B is shown in Figure 9 for the wildtype
and glycine mutant, respectively, for a 10ns trajectories. The RMSD was calculated for residue
22-26 chain B and 20-28 chain D after superimposing to itself separately. The black trace is
the RMSD of chain B for the wildtype, the red trace corresponds to the GlyB24 mutant and
the green curve is the RMSD difference between these two trajectories while the blue trace
is the average of the RMSD difference which is around 1 Å. This suggests that there is no
pronounced structural change for residues 22-26. Thus, the difference in binding free energy
between wildtype and glycine mutants may be caused by the covalent bonds between residues
and finally affect the dimerization free energy.
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Figure 9: RMSD of backbone of residue 22-26 chain B during 10ns trajectories.
The following 6 H-bonds (donor-acceptor) between chains B and D are analyzed in more detail:
Y26B-G24D, Y26B-G20D, G24B-Y26D, Y26B-F25D/G24B-T27D, G24D-Y26B, and Y26D-
G24B (see Table 2 - Table 2). The total number of H-bonds as a function of simulation time
between residues 22-26 (CHB) and residues 20-28 (CHD) are shown in Figure 10 for WI-
GlyB24. It can be clearly seen that there are fewer hydrogen bonds in this case. Therefore,
the contribution of H-bonds to the dimerization energy is reduced for the WI-GlyB24 mutant
compared to the WT. The histograms in Figure 10 underline this finding. The probability distri-
butions for the WT and SI-GlyB24 mutant are quite similar and show an average of 2.5 H-bonds
compared to only 1.2 H-bonds for the WI-GlyB24 mutant.
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Table 2: The hbonds between residue22-26 chain B and residue 20-28 chain D from B24Gly-SI
(∆G≈−43 kcal/mol) and B24Gly-WI (∆G≈−25 kcal/mol)
Donor Acceptor Occupancy
B24Gly-SI
CHB-Tyr26 CHD-GLy24 31%
CHB-Tyr26 CHD-Gly20 3 %
CHB-Gly24 CHD-Tyr26 7 %
CHB-Tyr26 CHD-Phe25 0.08%
CHD-Gly24 CHB-Tyr26 28 %
CHD-Tyr26 CHB-Gly24 36 %
B24Gly-WI
CHB-Gly24 CHD-Tyr26 5.8 %
CHB-Tyr26 CHD-Gly24 6.6 %
CHB-Gly24 CHD-Tyr27 0.04 %
CHB-Tyr26 CHD-Gly20 0.02 %
CHD-Tyr26 CHB-Gly24 10.3 %
CHD-Gly24 CHB-Tyr26 3.12 %
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Figure 10: The number of hydrogen bonds between residue 22-26 chain B and residue 20-28
chain D. (A) wildtype insulin dimer; (B) SI-B24Gly insulin mutant; (C) WI-B24Gly insulin
mutant.
The 6 H-bond distances for SI and WI are reported in Figure 11. For SI-GlyB24 (Figure 11(A)−
(F)), the distances between the donors (N, O) and acceptors (O, N) is≈ 3 Å for H-bonds Y26B-
G24D (Figure 11 (A), occupancy 31 %), G24B-Y26D (Figure 11 (B), occupancy 7 % ), G24D-
Y26B (Figure 11 (C), occupancy 28 %), Y26D-G24B (Figure 11 (D), occupancy 36 %); ≈ 5 Å
for Y26B-G20D (Figure 11 (E), occupancy 3 % ), and Y26B-F25D (Figure 11 (F), occupancy
0.08 %). Conversely, Figure 11 (G)-(L) report the same H-bonds for the WI-GlyB24 dimer.
The donor-acceptor distances are considerably larger. In some cases they increase to more than
6 Å, which means that no H-bond between chains B and D are formed and therefore reduce the
binding free energy accordingly.
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Figure 11: H-Bonds of donor and acceptor and water of Gly mutant. The distances (in Å) of
H-Bond donors and acceptors on residue 22-26 chain B and residue 20-28 chain D. (A)-(F): SI-
B24Gly mutant; (G)-(L): WI-B24Gly mutant. Green line : the donor-acceptor distance; black
line: the distance of the water-oxygen atom (Ow) closest to the protein-donor atom; red line: the
distance of the water-oxygen atom (Ow) closest to the protein-acceptor atom. Only hydrogen
bonds (both Ow-donor and Ow-acceptor) distances within 3.5 Å at the same time are showed.
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Because all simulations were carried out in explicit solvent, it is even possible to analyze
whether the H-bonds are replaced by interactions with the surrounding solvent. This is in-
deed the case. In Figure 11 distances between the water-oxygen atoms and the protein H-bond
donors are shown in black whereas the water-hydrogen atoms and the protein H-acceptors are
displayed in red. Only distances shorter than 3.5 Å are reported. This analysis shows in which
H-bonds a possible B↔D H-bond is replaced by a protein–water–protein H-bond. As can be
seen, the WI-GlyB24 dimer has many such water-mediated H-bonds which, however, are not
included in a typical MM-GBSA analysis.
Structural Rearrangement of the B20-B23 turn
It was supposed by Kaarsholm et al. that mutation of B24 by glycine may rearrange the C-
terminal decapeptide involving a perturbation of the B20-23 turn. This may allow the PheB25
residue occupy the position normally taken up by PheB24 in native insulin.14 It will be of inter-
est to verify this hypothesis with MD simulations. When phenylalanine in residue 24 position
is mutated by glycine, the pocket which is occupied by phenyl ring become empty. We com-
pared the structure of wild-type insulin dimer and GlyB24 insulin dimer (SI Figure 5 -Figure 6).
During the 10ns simulation, for wildtype insulin, the dihedral of aromatic side-chain of residue
24 and residue 26 is quite stable while dihedral of aromatic side-chain of residue 25 which is
outward from the dimer interface, is more flexible. For Gly24 mutant, for position 24 there
is no sidechain, the dihedral of sidechain of residue 26 is as stable as wildtype. However the
dihedral of residue 25 sidechain is much more stable compared to wildtype. From the structure,
for the wildtype insulin the Phe25 is much easily accommodated in the vicinity of the A19-A21
region, while for the Gly24 mutant, the Phe25 of Chain B is far away from the A19-21 region.
As the sidechain of PheB25 is outward of the dimer interface while the sidechain of PheB24
is inward of the interface, if the sidechain of PheB25 would occupy the pocket of PheB24, the
backbone of residue 24 to 26 will change subsequently. From SI-Figure7, the dihedral of back-
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bone of residue 24 to 26 of Gly24 mutant doesn’t dramatically changed compared to wildtype
insulin, which indicate 10ns trajectory is not long enough to see the changes for the Kaarsholm
hypothesis if any. Further more,dimer may be not the best system to study this motion, because
the interaction between chain B and chain D in the dimer interface.
Additionally, an alternative way were used to study whether residue 25 will move into the
position occupied by PheB24, via shifting the residue B24 up to the β− turn, then puting the
sidechain and backbone of residue 25 to the place where B24 were, and finally shifting residue
26-30 to compensate the space of residue 25. We observed that β− turn (Figure 12b, orange)
and β− sheet of chain B (Figure 12b, cyan) have more fluctuation compared to those of wildtype
insulin dimer (Figure 12a). It means that the structures of B23 to B28 undergo rearrangement
and inhibit this region from forming an antiparallel β−sheet with another monomer which is
necessary for dimer formation. The enthalpic stabilization free energy of this analog dimer is
around−24 kcal/mol, Table 3 compared to−45 kcal/mol for wildtype insulin, along 10 ns sim-
ulation. This indicates that this analog is not dimeric favored.
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Figure 12: Density map surfaces of Chain A and Chain B of insulin dimers. (a) Wildtype (b)
FB24Gly with PheB25 occupys the pocket of GlyB24. Blue: chain A; Red: residue 1 to 19 of
chain B; Orange: β− turn (residue 9 to 19); Yellow: residue 24; Cyan: residue 25; Green: β−
sheet (residue 26 to 30).
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Conclusion
Molecular dynamics (MD) simulations have been used to study the dynamical behavior of the
native and mutant insulin monomers and dimers. The native insulin dimer is very stable during
the MD simulation in solution, stays close to the starting X-ray structure and has dimerization
free energy around −12 kcal/mol absolute dimerization free energy (dimer favored) . In native
insulin monomer, chain A and helix of chain B are stable, but the C-terminal of chain B is
more flexible than in dimer. GlyB24 mutant and AlaB24 mutant insulin have lower propen-
sity for dimerization. AlaB24 dimer is slightly more stable than GlyB24 dimer, which may
be due to hydrophobic side chain. The aromatic ring of B24 plays a critical role in maintain-
ing the β− turn which tether the C-terminal of B-chain domain to hydrophobic core. D-Ala
mutant monomer has more flexible structure and less stable dimerization energy. Des-B25 has
monomeric character with very unstable dimerization energy. Des-B25 mutant experiences
large structural changes, which leads to the disappearance of hydrophobic surface at the C-
terminal of the B-chain. The large difference (≈ 20 kcal/mol) between the WI and SI-GlyB24
dimers most likely originates from H-bonds. They are formed directly H-bonds between chain
B and chain D in the case of SI dimer,whereas they are water-mediated in the case of WI dimer.
Our work provides an insight for designing analogues of human insulin and thus a therapy for
diabetes.
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Table 3: The contributions to the dimerization free energy at T = 300 K.
〈∆Evdw〉 〈∆Eele〉 〈∆Gele,desolv〉 ∆Gnp,desolv〉 〈∆G0bind〉+ 〈∆Gdesolv〉
wt1 -62.87(4.49) -102.32(38.74) 125.71(36.99) -9.48(0.65) -48.96(6.32)
wt2 -61.83(4.33) -87.89(39.17) 116.35(42.73) -9.65 (0.78) -43.01(5.75)
wt3 -58.34(5.03) -124.27(46.08) 143.45(38.66) -10.47(0.57) -49.63(9.37)
wt4 -66.59(4.36) -114.38(34.28) 146.23(32.58) -10.28(0.61) -45.02(6.46)
wt5 -59.45(3.68) -121.51(29.98) 145.68(28.10) -9.30(0.46) -44.58(5.82)
wt6 -61.36(3.91) -90.87(26.06) 119.87(24.76) -9.55(0.55) -41.91(5.62)
wt7 -62.85(3.40) -125.20(42.81) 149.39(44.43) -9.25(0.46) -47.90(5.02)
wt8 -60.93(4.02) -138.28(48.70) 161.65(47.78) -9.62(0.49) -47.17(6.23)
gly1 -62.36(4.08) -104.76(25.39) 130.29(24.99) -10.71(0.47) -47.54(6.16)
gly2 -53.32(4.12) -125.17(27.38) 151.12(22.78) -9.64(0.38) -37.01(7.38)
gly3 -58.09(4.93) -117.11(31.58) 141.39(31.27) -10.05(0.43) -43.86(6.53)
gly4 -51.11(6.17) -115.90(27.53) 147.56(22.56) -9.89(0.47) -29.34(11.69)
gly5 -56.11(5.94) -115.43(32.93) 140.98(31.20) -9.90(0.59) -40.47(7.88)
gly6 -53.39(4.35) -107.84(40.75) 132.83(38.36) -9.76(0.49) -38.16(7.27)
gly7 -64.08(6.42) -143.78(37.88) 170.47(34.54) -10.65(0.47) -48.04(8.34)
gly8 -55.28(4.50) -136.76(37.17) 176.94(35.75) -9.80(0.50) -24.90(6.81)
gly9 -57.52(3.92) -98.19(31.22) 145.35(27.56) -9.48(0.48) -19.84(10.31)
ala1 -54.16(3.82) -87.25(37.41) 116.56(36.76) -9.65(0.53) -34.50(6.59)
ala2 -61.34(5.91) -114.52(31.64) 142.50(31.27) -10.29(0.77) -43.64(7.36)
ala3 -58.00(3.96) -26.04(23.07) 53.51(20.69) -9.92(0.37) -40.45(6.11)
ala4 -53.76(4.66) -146.85(30.00) 167.65(28.81) -10.15(0.40) -43.10(7.69)
ala5 -56.85(4.19) -91.79(35.53) 120.17(34.27) -9.89(0.42) -38.36(7.49)
ala6 -58.52(5.49) -121.13(34.93) 150.53(31.66) -10.37(0.49) -39.49(7.97)
ala7 -56.20(3.99) -128.37(26.39) 149.69(26.18) -9.74(0.55) -44.62(6.51)
ala8 -55.04(3.96) -112.98(32.67) 141.54(30.39) -9.86(0.39) -36.34(6.29)
d-ala1 -60.39(5.06) -104.85(33.88) 142.77(30.85) -10.54(0.48) -33.00(9.47)
d-ala2 -59.20(4.41) -98.69(33.85) 128.59(31.52) -10.87(0.48) -40.18(7.07)
d-ala3 -42.83(5.26) -136.84(45.45) 167.94(41.11) -8.21(0.74) -19.95(8.68)
d-ala4 -58.63(4.25) -90.45(27.05) 135.90(24.50) -10.47(0.47) -23.64(8.10)
d-ala5 -45.51(5.82) -91.32(31.90) 127.91(31.78) -8.54(0.74) -17.46(10.07)
des-b251 -42.19(7.40) -35.89(23.36) 73.77(26.39) -7.37(1.17) -11.69(8.09)
des-b252 -48.57(4.45) -47.82(31.74) 84.51 (29.39) -8.28(0.59) -20.16(7.11)
des-b253 -40.76(5.03) -26.01(18.79) 51.12(18.38) -7.39(0.45) -23.03(5.50)
des-b254 -29.94(5.42) -67.34(29.45) 88.82(28.31) -6.96(0.76) -15.43(6.76)
des-b255 -44.47(5.21) -56.15(32.19) 92.43(29.57) -7.99(0.61) -16.19(6.47)
des-b256 -56.27(4.32) -46.75(49.52) 82.96(49.44) -9.27(0.58) -29.33(6.26)
des-b257 -44.52(5.82) -35.70(21.52) 68.84(23.67) -7.85(0.80) -19.24(8.19)
des-b258 -44.43(3.68) -30.09(18.94) 66.42(19.40) -7.48(0.45) -15.58(6.65)
b25turn24 -59.21(4.79) -63.19(26.05) 107.31(27.20) -8.94(0.57) -24.03(7.60)
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Figure 1: RMSD along the trajectories for the backbone atoms of the entire protein. (a) Wild-
type (b) B24Gly (c) B24Ala (d) B24D-Ala (e) Des-B25.
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Figure 2: Dimerization Free Energy of wildtype insulin dimer -panel (A) and B24Gly mutant
insulin dimer -panel (C) and (D).
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Figure 3: Structure of residue 24 to 26 of chain B in wild-type insulin dimer.
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Figure 4: Dihedral Angel of sidechain of residue 24 to 26 of wild-type insulin dimer. (a) -(c)
The dihedral angle of side-chain of residue 24 to residue 26 in wild-type insulin dimer. Black
is the dihedral of N-CA-CB-CG, Red is the dihedral of C-CA-CB-CG, Green is the dihedral of
CA-CB-CG-CD1. (a) residue 24; (b) residue 25; (c) residue 26. (d) - (f) the histograms of the
dihedral angles of side-chain of residue 24 to residue 26 in wild-type insulin-dimer: (d) residue
24; (e) residue 25; (f) residue 26.
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Figure 5: (a) -(b) The dihedral angle of side-chain of residue 25 to residue 26 in FB24Gly
mutant insulin dimer. Black is the dihedral of N-CA-CB-CG, Red is the dihedral of C-CA-
CB-CG, Green is the dihedral of CA-CB-CG-CD1. (a) residue 25; (b) residue 26. (c) - (d) the
histograms of the dihedral angles of side-chain of residue 25 to residue 26 in FB24Gly insulin
dimer: (c) residue 25; (d) residue 26.
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Figure 6: Pesudodihedral angle (four sucessusive CA atoms). black is the pesudodihedral for
β turn-(residue 20 to 23) in chain B; red is the for residue 24 to 26. (a) wildtype insulin; (b)
FB24Gly insulin; (c) Histogram for wildtype insulin; (d) Histogram for FB24Gly insulin.
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Figure 7: Ramachandran plot of β−sheet (residue 24 to 28) of chain B of (a) wildtype insulin
dimer (b) FB24Gly (c) FB24Ala (d) FB24D-Ala (e) Des-B25 insulin dimer during 10 ns trajec-
try length. One dot per ps, 10000 dots for each residue. Black is for B24, red for B25Phe, blue
for B26Tyr, green for B27Tyr, and cyan for B28Pro.
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6 Conclusion and Outlook
In this thesis some important dimerization processes in biological systems were addressed.
Quantum mechanical modelling methods (Density Functional Theory), together with
atomic molecular mechanism MD simulations were employed to characterize the dimer-
ization processes for c-di-GMP, endo-S-c-di-GMP, PleD, and insulin systems. Structural
changes and binding free energies were analyzed and very good correlations to experi-
mental data were obtained.
The studies of c-di-GMP and its analogue endo-S-CDG in solution and binding with
proteins in this thesis (Chapter 4) improved our fundamental understanding of this bac-
terial signaling molecule. It was demonstrated, that dimeric c-di-GMP is only marginally
stabilized even in high concentration. We revealed that changing the phosphodiester
backbone of c-di-GMP descreases the aggregation ability to support the designing of
non-aggregation-prone c-di-GMP like molecules. More investigation in this field is still
required for better understanding of the mechanism and for the development of anti-film
or anti-virulence drugs. And several aspects of this signalling molecule remain far from
being understood, such as the enzymatic process of PleD (biosynthesis of c-di-GMP upon
PleD dimerization), and the adaptor proteins that bind to c-di-GMP and transmit the
binding event into a processes leading to biofilm formation.
In Chapter 5 we investigated the hormone insulin, which upon dimerization leads to
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diabetes. The structural changes between monomers and dimers of the wildtype insulin
as well as several mutants (mutating the dimerization key residue phenylalanine B24 to
alanine, glycine, D-alanine, and Des-(Phe25)) were successfully characterized. Moreover,
the dimerization free energies of insulin and other analogues were obtained and indicated
the importance of residue phenylalanine B24 for insulin dimerization. Our work provided
an insight for designing analogues of human insulin and thus a therapy for diabetes.
In this thesis MM-GBSA was employed for calculating the dimerization free energy of
systems. MM-PB/GBSA methods are valuable tools used in computer-aided drug design.
But as with any other method, they have some limitations that need to be considered when
they are employed, such as they ignore protein-ligand/protein interactions bridged by
water molecules, as we found in this thesis. More research is required to ultimately develop
a fast, accurate and reliable method to calculate the binding affinity of ligand/protein to
protein for utilisation in drug discovery.
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